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ABSTRACT 
 
Neural circuitry, at its most basic level, is composed of multiple synaptic connections 
formed between the neurons within a circuit. These synaptic contacts are also the sites 
of local protein synthesis, which is required for long-term synaptic plasticity underlying 
learning and memory. The Fragile X Mental Retardation Protein (FMRP) functions as a 
translational repressor and is critical for fine-tuning local protein synthesis at synapses. 
Recently, we demonstrated that FMRP associates with the RNA helicase Moloney 
Leukemia Virus 10 (Mov10) in brain and modulates its translational activity through the 
microRNA (miRNA) pathway. FMRP is critical for normal cognition and our findings 
hypothesize a role for Mov10 in brain function. Additionally, Mov10 has a well- 
documented role of protecting genomic integrity by suppressing actively transposing 
retroviral elements called LINE-1 (L1) in cell culture systems. This becomes relevant 
when we consider the studies that propose an increase in endogenous 
retrotransposition in fetal brain as well as in the hippocampus and other regions of the 
adult brain during neuronal differentiation. Furthermore, L1 retrotransposition is more 
common in brain compared to other tissues in the body. Despite the many findings that 
show a role for Mov10 in suppressing retrotransposition, there are currently no studies 
describing its role in the developing or adult brain. In order to address theses gaps, we 
generated a knockout mouse model for Mov10 and found that the deletion of Mov10 
causes early embryonic lethality. We were able to show that lethality occurs prior to 
embryonic day 9.5 establishing a crucial role for Mov10 during mouse embryogenesis. 
We then used the externally developing Xenopus laevis embryos to establish the exact 
stage and cause of the Mov10 embryonic lethality. Our findings show that the blocking 
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of translation of the Mov10 maternal mRNAs in one-cell stage embryos results in a 
gastrulation defect at Stage 10 of Xenopus embryonic development.  RNA sequencing 
of embryos from Stage 10.5 of the Mov10 knockout shows an increase in mRNAs levels 
consistent with a miRNA-mediated role of Mov10 possibly at the Maternal to Zygotic 
Transition (MZT). In addition, we see that knockdown of zygotic Mov10 transcripts 
results in eye and ventricular neuronal differentiation defects in Stage 36 tadpoles. This 
suggests an important role for Mov10 in postnatal brain development. In agreement with 
this, we see that WT mice showed a significant increase in Mov10 protein levels in their 
brains from Postnatal Day 0 (P0) to P14 suggesting an important function for Mov10 
during this critical period of synapse formation and neuronal differentiation. Mov10 
expression was seen throughout the P1 brain including cortex, hippocampus and 
cerebellum and became localized mostly to the hippocampus in the adult brain. 
Interestingly, the subcellular localization of Mov10 was nucleo-cytoplasmic in P1 brains 
and predominantly cytoplasmic in the adult brain. The same age-dependent change in 
cellular localization was also observed in cultured neurons from Day In Vitro 0 (DIV0) 
and DIV14, suggesting a possible nuclear function for Mov10 at postnatal stages. 
Because of its critical role during development and postnatal increase in the brain, we 
further examined the Mov10 heterozygotes in this study. We found an increase in L1 
genomic DNA content in the Mov10 heterozygote brains at P2 compared to WT brains 
from the same stage, corroborating Mov10’s role in suppressing L1 retrotransposition. 
RNA isolation followed by sequencing from Mov10 immunoprecipitates (RNA-IP) at P2 
stage in brain shows that Mov10 bound retroelement RNAs belonging to the LINE-1 
family. Further verification showed that Mov10 specifically bound a retrotransposition-
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competent L1 RNA in mouse brain and that it inhibited the cDNA synthesis of this RNA 
in an in vitro assay. In addition, both the RNA-IP and iCLIP analysis of Mov10 RNA 
targets at P0-P1 brains followed by functional annotation showed that Mov10 bound 
significantly more mRNAs involved in cytoskeletal and actin binding. To investigate the 
role of Mov10 in cytoskeletal dynamics, we created a CRISPR-Cas9 knockout of Mov10 
in Neuro2a cells. The deletion of Mov10 in Neuro2a caused abnormally decreased 
neurite outgrowth on differentiation. We were able to rescue the defect by restoring 
Mov10 protein levels in the knockout cell line. Furthermore, culturing and staining of 
hippocampal neurons from Mov10 heterozygotes confirmed these results showing 
markedly short dendrites as seen in the Mov10 knockout Neuro2a cells. These findings 
point to an additional stage-specific role for Mov10 in modulating cytoskeletal dynamics 
that are key to synapse formation and pruning and eventually to the formation of normal 
brain circuitry. To investigate the behavioral output of reduced Mov10 levels on the 
brain, we conducted a series of behavioral tests on the Mov10 heterozygotes. We find 
that the Mov10 heterozygotes show increased activity in a novel environment using the 
Open-field test as well as increased anxiety in the Elevated- Plus Maze test, suggesting 
perturbed neuronal circuitry. The Mov10 heterozygotes tested normal in the Trace fear 
conditioning, Novel Object Recognition and Rotarod tests. These studies along with the 
neuron culture and knockdown assays suggest that Mov10 is important in developing 
and maintaining normal brain activity. This is the first study of Mov10 at an organismal 
level and in the brain. 
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CHAPTER 1 
INTRODUCTION 
 
RNA binding proteins play principal roles as modulators of synaptic activity in the central 
nervous system. They perform multiple functions from binding and modifying RNA, to 
transport and regulation of transcripts at the synapse in response to activity. They also 
function as part of Ribonucleoprotein complexes (RNPs) and RNA granules to effect 
various translational decisions and cellular fates [1]. A prominent class among these 
proteins is the RNA helicases. RNA helicases form a large group of enzymes that are 
primarily involved in the processing of RNA for regulating gene expression. They are 
classified into six Superfamilies (SFs) based on their structure and function and can act 
on a diverse array of substrates as well as perform a wide range of biochemical 
activities [2, 3]. The helicases of the SF1 and SF2 superfamilies share a catalytic core 
and act mostly on messenger RNAs (mRNAs) to regulate their function and 
reorganization [4].  They are present within complexes called messenger RNPs 
(mRNPs) at the synapse and regulate the synaptic mRNAs within this complex in a 
dynamic activity-dependent manner. This form of local protein synthesis is important for 
synaptic plasticity and memory consolidation [5].  Consequently, RNA helicases have 
been implicated in diseases of the nervous system, like DDX17 in Down syndrome [6, 
7]. Thus, RNA helicases play significant roles in ensuring proper synaptic physiology 
and normal brain function. 
The RNA helicase Moloney leukemia virus 10 (Mov10) belongs to this category 
of synaptic proteins and was found to coordinate the local translation of mRNAs through 
 2 
the RNA Induced Silencing Complex (RISC) pathway in cultured hippocampal neurons 
and in brain [8, 9]. Mov10 was first identified from a germline provirus integration study 
in which the Murine Moloney leukemia virus (Mu-MLV) was used to study the effects of 
retroviral insertions at random chromosomal locations [10]. The study generated 
multiple mouse substrains including the Mov-10 strain, named as such because it was 
the 10th substrain where the retrovirus had integrated. Subsequent studies showed that 
the provirus had integrated into intron 1 of a transcription unit, which was identified as a 
protein with a molecular weight of 110kDa and comprising of putative GTP-binding motif 
[11]. Consequently, the gene was called gb110 and was found to be regulated 
developmentally and in a cell-cycle specific manner. However, the knockdown of both 
alleles of gb110 gene in mouse ES cells did not affect the proliferation or differentiation 
in vitro and no further studies on Mov10 were published for over a decade [12]. Interest 
in Mov10 was revived in 2005 when it was identified as a novel player in the rising field 
of miRNA-mediated translational regulation of mRNA targets as an interactor of 
Argonaute 2 [13]. Importantly, a recent in vivo study from our lab showed that 
knockdown of Mov10 causes embryonic lethality in both mouse and Xenopus [14] 
(Chapter 3). In addition, reduced levels of Mov10 in brain resulted in neuronal and 
behavioral defects [14]. These studies emphasize the crucial role that Mov10 plays at 
two different stages namely embryonic and postnatal brain development and 
showcases the complex yet fascinating world of RNA helicases in the cell. 
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1.1 Characterization of Mov10 
 Gorbalenya and Koonin first observed in 1988 that proteins with DNA helicase 
activity contained several highly conserved sequence-motifs that are also shared by 
viral proteins encoded by RNA viruses [15]. Among these motifs, were the signature 
NTPase/ATPase motif of the P-loop proteins, which became the hallmark of all 
helicases. Thus all helicases are P-loop NTPases containing the Walker A  (also 
referred to as Walker I/Motif I) and Walker B (or Walker II/ Motif II) domains for NTP 
binding and hydrolysis [16]. 
SF1 and SF2 RNA helicases are characterized by the presence of two conserved 
domains, which forms the helicase core that is comprised of characteristic sequence 
motifs. Mov10 is classified as a Superfamily 1(SF1) helicase member based on its 
conserved helicase core that contains two similar domains that resemble the fold of 
bacterial RecA protein and are therefore often referred to as RecA-like domains. The 
arrangement of characteristic motifs within the helicase core results in the RecA like fold 
of these helicases. Like all helicases, Mov10 has the highly conserved Motif I 
(GPPGTGKT) and Motif II (DEAGH), which are present in Domain1 of the helicase core 
(Fig1.1) [17].  Additionally, phylogenetic analysis by sequence similarity clustered 
Mov10 with the Upf1-like helicases under the SF1 family [2] . Although Mov10 was 
initially identified as a GTP-binding helicase, recent characterization has shown that 
Mov10 utilizes ATP and shows a 5’ to 3’ directionality [18]. The domain structure of 
Mov10 has the conserved helicase core at the C-terminus and a proposed Cysteine-
Histidine (CH) domain at the N-terminal end. Cysteine and Histidine rich sequences 
have been reported in other proteins and are they known to be zinc-chelating residues. 
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They usually show conservation across species and have roles as Zinc finger domains 
[19]. Zinc finger domains coordinate a zinc ion to form a secondary structure that binds 
nucleic acid protein [20]. Here, we have aligned the entire Mov10 protein sequence from 
Human, Rhesus, Mouse, Xenopus and Zebrafish and find multiple conserved histidine 
and cysteine residues (Fig. 1.1 -highlighted in yellow). Based on conserved residues 
across Human and mouse, the proposed CH domain of Mov10 has a consensus of Cys- 
X15- Cys-X10-His-X2-Cys. Additionally, the Mov10 consensus CH domain does not 
exactly match with the Upf1 consensus CH domain sequence (Cys- X2-Cys-X9-His-X3-
Cys) [21], which is proposed to form a Zinc-finger binding domain based on the NCBI 
Conserved Domain Database (Fig. 1.2) [22]. It remains to be tested if the proposed 
Mov10 CH domain can fold in a Zinc-dependent manner or not. 
The alignment between multiple species in Fig.1.1 also shows that certain 
stretches of the N-terminus encompassing the histidines and cysteines that form the 
proposed CH domain (e.g. amino-acids 115-141,143-159, 163-172,187-194) are 
conserved between Human, Rhesus and Mouse but differ from other species. These 
sequences could have important roles in interacting with other proteins as shown for the 
HIV-1 protein [23]. The C-terminal core however is well conserved, especially the 
helicase Motif I and Motif II compared to the N-terminus across the different species 
(Fig. 1.1). 
 
1.2 Tissue expression and distribution of Mov10 
 
In a large-scale study to discover new genes expressed in human adult and fetal brain, 
Mov10 was identified as one of the new genes (referred to as KIAA1631) found to be 
differentially expressed in various adult brain regions and moderately expressed in 
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whole fetal brain [24]. Additionally, according to the Allen Brain Atlas, Mov10 shows low 
expression in the Olfactory bulb and cortical subplate in adult brain but its expression 
has not been examined across development in the mouse brain [25]. A recent study 
from our lab showed a developmentally timed increase in Mov10 protein levels in 
mouse fetal brain compared to adult.  At the subcellular level, Mov10 was found to be 
nucleocytoplasmic in postnatal brain and became predominantly cytoplasmic in the 
adult brain and in cultured Day In vitro 14 (DIV) hippocampal neurons [14] [8]. Nuclear 
localization of Mov10 was described once before in primary human fibroblasts where it 
was proposed to function in Polycomb-mediated suppression of a tumor suppressor 
gene [26]. In most studies, where Mov10 was ectopically expressed, a cytoplasmic 
localization to P-bodies has been reported [27] .  The cytoplasmic presence of Mov10 
was concluded by the researchers in [26] to be an effect of ectopic overexpression. 
However, we have examined endogenous Mov10 in HEK293 and in hippocampal 
neurons and find it to be cytoplasmic, as do others [8]. Thus, it only seems to be nuclear 
under specific circumstances.  
Besides the brain, Mov10 is highly expressed in the testes where it is 
cytoplasmic [14]. However, a specific function for Mov10 in the testes has not been 
shown. Interestingly, Mov10 shares very low C-terminal homology with another protein 
Mov10-Like1 (Mov10L1), which is germline specific and functions in the piRNA pathway 
[28].  Mov10L1 was also shown to inhibit retrotransposons during spermatogenesis [29, 
30], a function shared by Mov10 in brain and cell culture [14] [27]. 
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1.3 Cellular roles of Mov10 
1.3.1 Mov10 in retrotransposon biology 
Less than 2% of the human genome is protein-coding genes [31]. Approximately 50% of 
the genome is comprised of repeat elements and subsets of these are transposons. 
Transposons are defined as mobile genetic elements and can be either DNA 
transposons or retrotransposons based on their mode of action.  While the largely 
inactive DNA transposons move by excising themselves from one genomic location and 
inserting at another, retrotransposons move via an RNA intermediate. The RNA 
intermediate is reverse transcribed and the cDNA is inserted into a new genomic 
location by a process called Target-Primed Reverse Transcription (TPRT) [32]. 
Although, the vast majority of retrotransposons are silenced in the genome, a few of 
them are still active. These retrotransposon-competent elements belong to the 
autonomous Non-Long Terminal Repeat (Non-LTR) class and are called Long 
Interspersed Elements-1 or L1. L1s are the only known active elements in eutherians 
[33]. L1s are also co-opted by other non-autonomous retrotransposons like SINEs 
(Short Interspersed Elements) and SVAs (SINE-R, VNTR, Alu) that enable them to 
mobilize in the genome. Needless to say, L1s are tightly regulated in cells to prevent 
deleterious insertions in the genome. One of the proteins that strongly suppress L1s is 
Mov10. Many studies have reported this function for Mov10 both in cell culture systems 
and in the developing brain [27, 34], [14]. The proposed mechanism by which Mov10 
suppresses L1 elements is not fully understood. Multiple lines of investigation have 
shown conclusively that Mov10 binds the L1 mRNA and also associates with the L1 
RNP [27, 35], [14]. The proposed mechanism of Mov10 inhibition is linked to its 
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presence in Processing bodies (P-bodies), where the Mov10 bound L1 RNA is 
presumably degraded. The presence of Mov10 in the nucleus suggests an additional 
mechanism where the L1 mRNA is prevented from being reverse-transcribed by the L1 
endonuclease and reverse transcriptase ORF2p at the site of insertion. TPRT requires 
that the nicked DNA strand with the 3’OH overhang be made available for ORF2p to 
use as a primer for reverse transcribing the L1 mRNA. Additionally, a recent study also 
showed that G-rich tracts stimulate L1 retrotransposition and we have shown that 
Mov10 preferentially binds G-rich regions [9, 36]. Based on these findings, we propose 
a possible model where Mov10 binds the G-quadruplexes found in the 3’UTRs of L1 
mRNAs [37]. This binding of L1 mRNAs within the L1 RNP could occur in the nucleus or 
in the cytoplasm. Additionally, Mov10 also associates with ORF2p through its N-terminal 
via a protein-protein interaction [14]. Having thus established itself as a part of the L1 
RNP, Mov10 then proceeds to unwind the G-quadruplexes within the L1 mRNA in a 5’-
3’ direction while ORF2p reverse transcribes the L1 mRNA in the 3’ to 5’ direction at the 
site of insertion. The opposing movement of Mov10 thus sterically blocks ORF2p from 
reverse transcribing and inserting the L1 mRNA (Fig.1.3).  
 
1.3.2 Mov10 and viral suppression 
Retroviruses are obligate parasites that require host proteins to support their entry and 
establishment inside cells. As such they interact with host factors that either support or 
inhibit their life cycle [38].  Of these many factors, Mov10 has been shown to inhibit 
retroviral activity of HIV-1, SIV, MLV, HCV and HBV retroviruses and more recently 
Enterovirus 71 and Dengue virus [39-44]. Thus Mov10 is considered to have a broad 
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anti-retroviral activity. Over the years many more studies have confirmed this finding 
and added to the molecular understanding of the anti-retroviral properties of Mov10. 
Overexpression of Mov10 inhibits viral activity both in the virus producing cells and the 
target cells. It has been shown to decrease the viral particles and infectivity rates in the 
producer cells possibly by its interaction with the viral Gag protein through its N-
terminus [41]. Besides decreasing the infectivity of viral particles, Mov10 is also 
packaged inside the virions and inhibits the reverse transcription of the viral mRNA in 
the target cells [39, 40]. Interestingly, this function is similar to its role in inhibiting LINE1 
retrotransposons from integrating into the genome [34] [14] and might share molecular 
features. Although Mov10 prevents the reverse transcription step in L1 
retrotransposition and viral suppression, physiological levels of Mov10 were enough to 
inhibit retrotransposons but did not prevent infection by exogenous viruses [45] 
suggesting that Mov10 could have been evolutionarily co-opted for suppressing 
retroelements by being activated through a common cellular signal for example the type 
I IFN pathway for invading RNA viruses [46]. The activation of Mov10 could be through 
sequence or structural elements within the single- stranded RNA molecule, be it a virus 
or a LINE element.  This also suggests that Mov10 has an evolutionary past in viral 
infectivity and a recent study [47] demonstrates this complex role for Mov10, where the 
authors show that normal endogenous levels of Mov10 enhance nuclear viral mRNA 
export and subsequently increase the expression of Gag protein during HIV-1 infection. 
The opposite has been shown for the Influenza A virus, where Mov10 bound the 
nucleoprotein of the viral complex and prevented its interaction with importin-α 
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effectively preventing the nuclear transportation and replication [48]. Thus, the role for 
Mov10 in suppressing viral infectivity though well established, is far from complete. 
 
1.3.3 Mov10 in miRNA mediated translational regulation  
Mov10 is widely described as associating with RISC and was also found to co-
immunoprecipitate with the microRNA effector protein Argonaute 2 (Ago2) in an RNA 
dependent manner [49-51].  Since mRNAs have a high degree of secondary structure 
and microRNA Recognition Elements (MREs) in their 3’ Untranslated regions (UTRs) 
cannot be unwound by Ago2, it is possible that Mov10 helps to open up these structures 
for miRNA mediated regulation [52]. Multiple studies point to a role for Mov10 in miRNA-
mediated translational suppression of reporters and neuronal mRNAs at synapses and 
in the brain [8, 13, 52]. However, the role of Mov10 in miRNA-mediated translation of its 
targets could be modulatory in nature based on its association with other RNA-binding 
proteins such as FMRP. Here, the fate of the commonly bound mRNAs depended on 
the binding site of FMRP and Mov10 and the accessibility of the MRE to AGO2. Thus 
even though the larger fate of most mRNAs is miRNA-mediated translational 
suppression, some of the mRNAs are protected from AGO2 and undergo translation. [9, 
52]. Additionally, it has been shown in one specific case that endogenous Mov10 is not 
necessary for the let-7 miRNA-mediated suppression of a reporter construct in HeLa 
cells [45]. In this particular case, it is possible that the MRE was not buried in a 
secondary structure or that other helicases are involved in unwinding these specific 
3’UTRs. Therefore it is conceivable that Mov10 has more of a modulatory role and 
regulates a certain pool of targets through the RISC pathway and that this function of 
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Mov10 depends on the associated protein factors within the RNP complex. In addition 
to its RISC-mediated function, Mov10 was recently shown to associate with UPF1 and 
participate in the Nonsense-mediated decay (NMD) pathway [18]. These findings only 
add to the understanding that RNA helicases rarely have dedicated cellular roles and 
are often co-opted by different pathways that use RNA metabolites [17]. 
 
1.4 Mov10 in embryonic development  
Expression of Mov10 in the developing whole embryo was first seen as early as 
embryonic day 12 in mouse [11].  However an embryonic stem cell knockout of both 
copies of Mov10 did not affect the differentiation of the embryo into the three germ 
layers and it was concluded that Mov10 was not required for ES cell proliferation and 
differentiation [12]. Therefore, it was extremely surprising that a complete knockout of 
Mov10 in mouse and Xenopus caused early embryonic lethality [14], Chapter 3. 
Translation- blocking morpholino based knockouts of maternal Mov10 transcripts in 
Xenopus shows that the embryos do not complete gastrulation and neural tube 
formation (Chapter 3). The Mov10 knockout embryos did show formation of the somites 
(mesoderm) and neural tube (ectoderm) suggesting that germ layer differentiation is 
proceeding as in the mouse ES cells [12, 53].  However, the Mov10 knockout embryos 
fail to complete gastrulation at Stage 10 in Xenopus, which is comparable to embryonic 
day 6.75-7 in mice based on the development of the Spemann’s organizer [54]. These 
defects could possibly be due to Mov10’s role in miRNA-mediated regulation of the 
Maternal to Zygotic Transition (MZT) in the developing embryos (Chapter 3). MZT 
occurs universally in all animals and is the step where maternally deposited transcripts 
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are degraded and zygotic transcription is activated [55].  The stage of MZT is species -
specific and occurs at the two-cell stage in mouse. MZT in mouse embryos is 
dependent on the RNAi machinery since a knockdown of Ago2 causes a developmental 
arrest of embryos at this stage [56].  Ago2 is absolutely critical for miRNA-mediated 
degradation of maternal transcripts at MZT but Mov10 might have a broader role and it 
is possible that the gastrulation defects arise due to pleiotropic effects caused by 
maternal Mov10 knockout.  The genes that are largely affected in the Mov10 knockout 
embryos belong to cytoskeletal and cellular movement categories by Gene Ontology 
analysis, which explains the observed defect in gastrulation. Gastrulation involves an 
evolutionarily conserved series of cellular rearrangements and movements that are 
highly coordinated and dependent on cytoskeletal components [53]. Thus the large 
scale rearrangements required for proper gastrulation might be perturbed in Mov10 
knockout embryos due to a mysregulation of mRNAs that are needed at critical time-
points and concentrations in the embryo to effect this transition. This could be due to the 
defective MZT beginning at an earlier stage and leading to an aberrant transcriptional 
environment at gastrulation. 
 
1.5 Mov10 in the developing brain  
Mov10 is present in mature neurons and at synapses. NMDA stimulation leads to its 
rapid degradation by the proteasome pathway and consequently relieves translation 
suppression [8, 9 , 24]. However, until now, there was no systematic study of this 
protein in the developing brain [14]. In this recent study published by our group, Mov10 
protein levels showed a developmental increase in whole brain and was about 40 fold 
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higher than the adult brain at postnatal stages P0-P2 [14]. This is an extremely 
important stage in brain development where a host of important events like neuronal 
differentiation, synaptogenesis and synaptic pruning occurs to influence brain structure 
and circuitry [57]. The pattern of Mov10 distribution in whole brain showed a transition 
from being ubiquitous in P0 brain to becoming restricted to the hippocampus in adult 
brain. Mov10 also showed a change in cellular localization from nucleocytoplasmic at 
P0-P2 brain to predominantly cytoplasmic in the adult brain. This developmentally timed 
increase and nuclear localization of Mov10 at postnatal stages was shown to be 
important for regulating LINE1 elements that become active during neuronal 
differentiation [58]. In addition to its nuclear role, cytoplasmic Mov10 also bound 
cytoskeletal mRNAs in postnatal brain and regulated neurite outgrowth in a knockout 
cell line, reminiscent of its function in cytoskeletal remodeling during embryogenesis. 
Interestingly, the Mov10 heterozygote mice show increased genomic LINE1 content, 
decreased hippocampal dendritic arborization as well as behavioral deficits suggesting 
an important role for Mov10 in the formation of normal brain circuitry [14]. This is 
important since several studies have shown that the Mov10 gene is present in Copy 
Number Variants (CNVs) seen in individuals with intellectual and developmental delay 
[59-61]. Besides establishing a significant role for Mov10 in brain, this study also raises 
many interesting questions such as how are the protein levels of Mov10 regulated 
across development, how does Mov10 shuttle from the nucleus to the cytoplasm and 
why does its localization and distribution change as the brain develops. In addition, 
Mov10’s preference for cytoskeletal mRNAs both in embryonic development and in 
postnatal brain is intriguing and suggests a functional specificity belying this otherwise 
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multifunctional helicase. The Fragile X mental retardation protein (Fmrp) also 
preferentially binds RNAs involved in neuron projection [62]. Because Fmrp binds 
cobound mRNAs before Mov10 [9], this could serve as an initial selection for Mov10 to 
preferentially bind actin/cytoskeletal/neuron projection RNAs. It also lends precedence 
to Mov10 as an important candidate in neurological disorders with underlying 
cryoarchitectural deficits such as Autism and Alzheimer’s disease [63]. 
 
1.6 Conclusion 
The studies of the RNA helicase Mov10 have rapidly progressed from its earliest 
categorization as a RISC component to its recent prominence as a critical player in 
embryonic and normal CNS development. Additionally, as outlined above, Mov10 also 
participates in many other important cellular events such as retroviral and 
retrotransposon suppression. These myriad roles of Mov10 is made possible by its 
association with other RNA binding proteins as well as its assimilation into functional 
structures such as mRNPs, P-bodies and other cytoplasmic aggregates. The 
emergence of a preference for Mov10 in cytoskeletal regulation suggests a new 
direction of research for this fascinating protein.   
 The work presented here outlines the first study of the RNA helicase Mov10 
during embryonic development and postnatal brain development. Chapter 2 deals with 
the expression and function of Mov10 in the developing mouse brain. Chapter 3 shows 
the essential role that Mov10 plays during embryonic development using Xenopus 
laevis model system. Chapter 4 talks about the accessory role that FMRP plays in the 
miRNA pathway and Chapter 5 is a conclusion of the findings in this thesis. 
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1.7 Figures 
Figure 1.1 
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Figure 1.1 (cont.) 
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Figure 1.1 (cont.) Evolutionary conservation of Mov10- Amino acid alignment of Human 
(NM_020963.4), Rhesus monkey (NM_001261223.1), Mouse (NM_008619.2), Xenopus 
(XM_018246602.1) and Zebrafish (NM_001044342.2) are shown. The conserved 
Cysteine and Histidine residues between human, rhesus and mouse that form a 
consensus CH domain are highlighted in yellow. The Motif I and Motif II of the helicase 
core which is required for ATP binding and hydrolysis are in bold. Asterisks marks 
conservation across all five genera, colon indicates strongly similar group conservation; 
period indicates weakly similar group conservation and dashes are regions of no 
conservation.  
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Human 
 
Mouse 
 
UPF-1 consensus sequence 
 
 
Figure 1.2. Proposed CH domain (amino acid residues 93-305) within the N-terminus of 
human Mov10 (NM_020963.4, NM_001130079.2, NM_001321324.1) based on [18] 
along with the same amino-acid residues from mouse Mov10 (NM_008619.2, 
NM_001163441.1). The Upf1 consensus sequence was adapted from [21] and derived 
from human UPF1, S.cerevisiae UPF1 and S.pombe UPF1-like. The conserved 
residues are shown in red. 
 
 
 
 
 
 
 
 
KLGSDISKHHKSLLAKIFYDRAEYLHGKHGVDVEVQGPHEARDGQLLIRLDLNRKEVLTLRLRNGGTQSVTLTHLFPLCRTPQF
AFYNEDQELPCPLGPGECYELHVHCKTSFVGYFPATVLWELLGPGESGSEGAGTFYIARFLAAVAHSPLAAQLKPMTPFKRTR	
KPGSNISKQHRSLLARIFHDRAEYLHGKHGVDVEVQGPHEARDGQLLIHLDLNRKEVLTLRLRNGGSKPVTLTHLFPLCWTPQ
FVFYHGEQDLPCPLGPGESYELHIYCKTSIVGYFPATVLWELLGPGESGAEGAETFYIARFLAAVAHSPLAAQLKPTTPFKRPP	
CXYCGI+XXXXUUXCXXXKKWFCNX+XXXXXSHIUXHLVXX+XXXVXLHXXXXLXXTVLECYNCGX+NVFLLGFUXAKXXXVVVLLCRXPC	
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Figure1.3. Proposed model for Mov10 in LINE1 suppression - 1) L1 mRNA is 
transcribed by RNA PolI and bound by Mov10. 2) Mov10 binds at the G-quadruplex 
present in the L1 3’UTR, either in the nucleus or the cytoplasm (denoted by question 
mark). 3) The L1 mRNA is translated and assembled into the L1 RNP (4) and is 
exported back into the nucleus (5). 6) At the site of insertion, the ORF2p which binds to 
the polyA tail [64] of the L1 mRNA attempts to reversed transcribe the L1 mRNA into 
cDNA and encounters steric hindrance from Mov10 which is moving in the 5’ to 3’ 
direction to unwind the G-quadruplex. 7) This prevents the cDNA synthesis and 
subsequent TPRT and insertion of the L1 at the genomic locus.  
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CHAPTER 2 
MOV10 SUPPRESSES RETROELEMENTS AND REGULATES NEURONAL 
DEVELOPMENT AND FUNCTION IN THE DEVELOPING BRAIN1. 
 
2.1 Abstract   
Background: Mov10 is an RNA helicase that mediates access of the RNA-induced 
Silencing Complex to mRNAs. Until now, its role as an RNA helicase and as a regulator 
of retrotransposons has been characterized exclusively in cell lines. We investigated the 
role of Mov10 in mouse brain by examining its expression over development and 
attempting to create a Mov10 knockout mouse. Loss of both Mov10 copies led to early 
embryonic lethality. Results: Mov10 was significantly elevated in postnatal murine brain 
where it bound retroelement RNAs and mRNAs. Mov10 suppressed retroelements in 
the nucleus by directly inhibiting cDNA synthesis while cytosolic Mov10 regulated 
cytoskeletal mRNAs to influence neurite outgrowth. We verified this important function 
by observing reduced dendritic arborization in hippocampal neurons from the Mov10 
heterozygote mouse and shortened neurites in the Mov10 knockout Neuro2A cells. 
Knockdown of Fmrp also resulted in shortened neurites. Mov10, Fmrp and Ago2 bound 
a common set of mRNAs in brain. Reduced Mov10 in murine brain resulted in anxiety 
and increased activity in a novel environment, supporting its important role in the 
development of normal brain circuitry. Conclusions: Mov10 is essential for normal 
neuronal development and brain function.  Mov10 preferentially binds RNAs involved in 
actin binding, neuronal projection and cytoskeleton. This is a completely new and 
critically important function for Mov10 in neuronal development and establishes 
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precedent for Mov10 being an important candidate in neurological disorders that have 
underlying cytoarchitectural causes like Autism and Alzheimer’s disease. 1  
 
2.2 Introduction 
Mov10 is a Superfamily 1 (SF1) RNA helicase that binds to G-rich secondary 
structures and unwinds RNA in a 5’-3’ direction in an ATP-dependent manner [1, 2]. 
Mov10 was originally described as associating with RNA-induced silencing complex 
(RISC) factor Argonaute 2 (Ago2) and was required in microRNA (miRNA)-guided 
cleavage of a reporter [3]. Mov10 also has roles in nonsense-mediated decay, 
suppression of viral RNAs and retrotransposition in cultured cells [1, 4, 5]. We found 
that Mov10 associates with the Fragile X mental retardation protein (Fmrp) in adult brain 
to regulate translation of a commonly bound set of RNAs by modulating their 
association with Ago2 [2]. Fmrp is required for normal cognition and our findings 
suggested a possible role for Mov10 in brain function. Currently, there are no studies 
describing a role for Mov10 in the developing brain. 
In the central nervous system, RNA helicases function by affecting neuronal 
differentiation, RNA localization, cell morphology and apoptosis [6]. Examples of 
helicases that are miRNA-related include DHX36, which is required for dendritic 
localization of pre-miR134 [7] and DDX6, which binds TRIM32 to increase the activity of 
RISC [8]. Importantly, none of these helicases could functionally compensate for Mov10 
since the Mov10 knockout is embryonic lethal in mouse.  
																																								 																				
1	This	chapter	has	been	accepted	for	publication	in	BMC	biology	and	is	reprinted	under	the	
terms	of	the	Creative	Commons	Attribution	4.0	International	License	
(https://www.biomedcentral.com/licensing).	
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Mov10 is also significantly elevated in brain shortly after birth through 
adolescence. Isolation of Mov10-associated RNAs from P2 brain reveals two critical 
roles for Mov10 in early brain development: a suppressor of retrotransposition and a 
regulator of neuronal projections. Two-thirds of the Mov10-associated RNAs encode 
retroelements including Long Interspersed Nuclear Elements (LINEs) while the rest of 
the mRNAs encode proteins involved with neurite outgrowth and cytoskeleton.  
Mov10 is a strong suppressor of endogenous transposition of L1, an active LINE 
element in cultured cells [5, 9]. During neuronal differentiation, there is increased L1 
retrotransposition in hippocampus and several regions of the adult brain. We 
hypothesize that Mov10 is elevated in postnatal brain to suppress retrotransposition, 
which is highly active during this time in brain [10]. As neurons mature and arborize, 
Mov10 regulates the translation of actin binding proteins and cytoskeleton, which is 
required for neuronal migration and function. This is the first study to show a role for 
Mov10 during embryogenesis and in postnatal brain development and function. We 
propose that Mov10 is vital for viability and for normal CNS development and function. 
 
2.3 Results 
Mov10 is elevated in postnatal mouse brain 
Since Mov10 functionally associates with Fmrp [2], we examined Mov10 
expression in the postnatal murine brain across development. As early as embryonic 
day 18, there was a higher level of Mov10 in whole brain compared to adult (Fig.2.1A, 
compare first and last lanes). Mov10 expression continued to rise at birth (P0) and 
remained elevated over adult levels until P10-P14 when it began to decline (Fig.2.1A). 
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We observed the same increase in postnatal Mov10 levels in a different mouse strain 
(FVB, Additional file 2.1A) and it was independent of sex (Additional file 2.1B).  We 
conclude that Mov10 is elevated in postnatal and juvenile mouse brain, suggesting an 
important role for Mov10 in the developing brain.   
To determine the pattern of Mov10 expression, we stained sagittal sections of 
postnatal and adult brain to examine if Mov10 was elevated in specific brain regions. 
Mov10 was highly expressed throughout P1 brain, including cortex, hippocampus, 
cerebellum, midbrain and hindbrain (Fig.2.1C). In contrast, there was very little Mov10 
expression in adult brain except in hippocampus (Additional file 2.2A, right). However, 
the hippocampus and cortex of P0 mice expressed much more Mov10 than did the adult 
hippocampus and cortex (Additional file 2.2A, 2.2B). In addition, neurons appeared to 
have both nuclear and cytoplasmic staining in the P0 mice compared to the adult 
(Additional file 2.2A, see inset).  
Since Mov10 has previously been described as cytoplasmic in both cultured cells 
[3, 5] and in cultured hippocampal neurons [11], we examined Mov10 localization in P2 
brain. We observed Mov10 in the nucleus as well as cytoplasm (Fig.2.1D-F, P2). In 
contrast, Mov10 was primarily cytoplasmic in adult hippocampus (Fig.2.1G-I, Adult). To 
verify these age-dependent differences in the intracellular localization of Mov10 and 
using a different Mov10 antibody, we examined hippocampal neurons cultured from P0 
mice. We found that Mov10 was distinctly nuclear in Day In Vitro (DIV) 1 neurons 
(Additional file 2.2C, DIV1) compared to DIV14 neurons, where it was primarily 
cytoplasmic (Additional file 2.2C, DIV14), as previously reported [11]. We further 
confirmed the nuclear presence of Mov10 by biochemical fractionation of P2 brain 
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(Additional file 2.2E). Mov10 expression was also examined in testes, where it is highly 
expressed, and found to be cytoplasmic (Additional file 2.2D).  We conclude that Mov10 
is in the nucleus and the cytoplasm in postnatal brain.  
 
Mov10 knockout is embryonic lethal 
Mov10, like Fmrp, is expressed throughout the brain. In order to study the 
function of Mov10 at postnatal stages in brain, we attempted to generate a Mov10 
knockout mouse using an ES cell with one copy of Mov10 targeted by a gene trap 
vector (Additional file 2.3). After screening 156 pups from heterozygote crosses, we 
found no viable Mov10 knockouts (Table 2.1) and concluded with >95% confidence that 
the Mov10 knockout has an embryonic lethal phenotype [12]. To determine when 
Mov10 exerts its crucial effect, we genotyped embryos from E9.5 and E12.5 and failed 
to detect any Mov10 knockout embryos at these early stages  (Table 2.1). Based on this 
data, we conclude that Mov10 is essential for embryonic development in mouse. 
 
Mov10 suppresses LINE retrotransposition in the nucleus 
To investigate the role of Mov10 in early brain development, we performed RNA-
immunoprecipitation (RIP) from P2 brains and sequenced the RNAs bound to Mov10. 
The total number of reads was 98,884,367; the number of aligned reads was 
71,522,027 (74.59% aligned) and the number of uniquely aligned reads was 57,005,129 
(59.45%). We used RIPSeeker to identify RNAs significantly enriched over input RNA 
[13] and found 2996 RIP peaks: 1313 overlapped with repeat elements from the Long 
Terminal Repeat Family (LTRs), the autonomous Non-LTR family of LINEs, and the 
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non-autonomous SINEs in the RepeatMasker database (Fig.2.2A, Additional File 2.4-
see online) and 525 peaks overlapped with RefSeq, indicating that they were mRNAs 
(Fig.2.2A, Additional File 2.5-see online). We validated the RIPSeeker result by 
immunoprecipitating Mov10 from P2 mouse brain and performing RT-PCR on an 
endogenously active autonomous retrotransposon mL1TF as well as Prrc2b, a brain 
mRNA target of Mov10 (Fig.2.2B) [14]. Although Mov10 has previously been shown to 
bind the L1 transcript [5] we showed here that it binds L1 transcripts from the 
retrotransposition-competent TF subfamily of mouse L1s (Fig.2.2B). These primers have 
been used before by others [15]; however, it is possible that the RT-PCR to detect L1 
expression is off-targeting to L1 sequence fragments that might be contained in 
mRNAs. Thus, we cannot rule out the possibility that some of the immunoprecipitated 
signal could be due to the presence of an mRNA that happens to contain the L1 primer 
target sequence.  
Our hypothesis is that Mov10 binds the RNA of retroelements and inhibits their 
transposition in developing brain. To test this hypothesis, we quantified the amount of 
genomic L1 in P2 brains from heterozygous Mov10 knockout mice compared to WT, 
hypothesizing that the reduction in Mov10 would lead to an increase in L1 
retrotransposition events, as observed in the MeCP2 knockout mice [16]. The qPCR 
was done using genomic DNA treated with Exonuclease1 to remove any unintegrated 
cDNA and RNAse H to remove DNA-RNA hybrids that might artificially contribute to the 
observed increase in LINE content. Similar to the MeCP2 study, we found a 2-fold 
increase in L1 genomic content in the Mov10 heterozygotes (Fig.2.2C, 2.2D, Additional 
file 2.6-see online), supporting a role for Mov10 in L1 suppression in developing brain.  
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 APOBEC3G is an RNA editing enzyme that plays a key role in regulating 
retrotransposition by directly binding reverse transcriptases [17, 18] and also by binding 
RNAs to sterically block reverse transcriptase (RT) activity [19, 20]. To determine 
whether Mov10 was able to block RT activity, we incubated equal molar amounts of 
Mov10 and SuperScript III Reverse Transcriptase, an engineered version of M-MLV RT, 
and then performed a reverse transcription reaction in which total RNA from P2 brains 
was added. Reverse transcription of both L1 RNA and Prrc2b RNA was blocked by 
addition of Mov10. In contrast reverse transcription of the Gapdh transcript, which is not 
bound by Mov10 [2] was only partially inhibited (Fig.2.2E, 2.2F, Additional file 2.6-see 
online). We also tested purified recombinant human FMRP, another RNA binding 
protein, in this assay and found that the addition of FMRP did not have an effect on 
cDNA synthesis (Fig.2.2E). Thus, Mov10 blocked reverse transcription of its bound 
targets more efficiently than that of non-target RNAs. Others agree that Mov10 is a 
suppressor of retrotransposition [5] but the mechanism is controversial. The LEAP 
assay (L1 element amplification protocol) [21], which measures the ability of purified L1 
RNP to reverse transcribe the bound L1 RNA was used in [5] to show that Mov10 
suppresses reverse transcriptase activity, which agrees with our results using 
recombinant His-tagged Mov10 purified from Sf9 cells [2]. Our data however contradicts 
the study in [22] where the LEAP assay was performed from L1 RNPs isolated from 
HeLa cells and treated with recombinant Mov10 (Origene). Possible explanations for the 
differing results are that the sources of recombinant Mov10 are different, as are the 
methods of purification, which could have affected the presence of cofactors. Mov10 
purified from mammalian cells may also have post-translational modifications that are 
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not present in the Sf9 purified Mov10. Li and colleagues concluded that Mov10 blocks 
retrotransposition by facilitating L1 RNA degradation and its helicase activity is required 
for this function [9]. We tested the helicase-deficient mutant of Mov10, where a 
conserved lysine in Motif I has been mutated to alanine [1], in our in vitro assay and 
found that it does not suppress the cDNA synthesis of either mL1TF or Prrc2b (Fig 2.2F, 
Additional file 2.6-see online). Thus, the helicase function of Mov10 is required to block 
RT activity.  
To determine if Mov10 directly bound RT, we coupled either SSRTIII or BSA to 
beads and found that only SSRTIII efficiently captured Mov10. Additionally, we 
performed the capture using either the C-terminal half or the N-terminal half of Mov10 
and found that only the N-terminal half could bind SSRTIII (Fig.2.2H). The unstructured 
N-terminus of Mov10 has been implicated in inhibiting HIV-infectivity, though the exact 
mechanism is unclear [23]. Our data suggest that Mov10 binds reverse transcriptase 
through its N-terminal region and unwinds the L1 RNA using its C-terminal helicase 
domains. Importantly, Mov10 directly bound ORF2p, which is the RT/endonuclease 
encoded by L1 (Fig.2.2I). RNAse treatment did not significantly change the amount of 
immunoprecipitated ORF2p (the difference between the indicated ratios is not 
significant), suggesting a protein-protein interaction. We conclude that Mov10 is 
elevated in the nucleus during postnatal brain development when retrotransposition is 
active to bind retroelement RNAs and block reverse transcription, which is a critical step 
for retrotransposon insertion.   
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Mov10 associates with cytoskeletal mRNAs to regulate neurite outgrowth 
Approximately one-third of the Mov10-associated RNAs in postnatal brain RIP-
seq were mRNAs (Fig.2.2A). We used the DAVID Bioinformatics database to analyze 
the Gene Ontology (GO) terms assigned to the 525 RNAs, which revealed axon, neuron 
projection, growth cone and dendrite among the most significant categories (Fig.2.3A, 
p-values 9.1x10-9, 1.3x10-8, 7.8x10-7, 8.6x10-7, respectively). To independently verify 
this result, we performed individual nucleotide cross-linking immunoprecipitation (iCLIP) 
on brains isolated from P0-P1 mice (Fig.2.3B, right panel) and obtained 92,798,446 
reads; after quality trimming and deduplication, there were 5,269,506 reads. Further 
analysis revealed 61,471 unique tags present in the Mov10 IP compared to 3545 tags in 
the irrelevant IP. 2988 of the tags aligned to the genome, 2333 uniquely aligned and 
729 regions were identified. The gene identities are in Additional File 2.7. GO analysis 
using a P1 brain transcriptome as background revealed that RNAs encoding proteins 
involved in neuron projection had the lowest P value (Figure 2.3B, Cellular 
Compartments category). Under GO category Molecular Function, actin binding and 
protein binding were the most enriched (Figure 2.3B bottom). In addition, the GO term in 
the Biological Process category with the lowest P value (9.1x10-5) was actin cytoskeletal 
organization. These data suggest a cytoplasmic role for Mov10 in regulating actin and 
cytoskeletal mRNA expression in the postnatal brain.  
To determine if Mov10 functions in neurite outgrowth, we used CRISPR-Cas9 to 
knockout Mov10 (Additional file 2.4A) in Neuro2a (N2a) cells, a murine neuroblastoma 
that has long branching processes when grown on a substrate [24]. We induced 
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differentiation of the WT and Mov10 knockout (KO) N2a cells and found significantly 
reduced neurite length in the Mov10 KO cell line compared to WT (Fig.2.4A-D) that 
could be rescued upon re-introduction of the Mov10 transgene, suggesting that this 
phenotype was directly attributable to the loss of Mov10 and not an off-target effect.  
To determine how Mov10 participates in differentiation, we isolated RNA from 
undifferentiated and differentiated WT and KO N2a cells and performed high-resolution 
RNA-seq analysis. Samples were sequenced extremely deep to around 350,000,000 
paired-end 100 base pair (bp) to capture lowly expressed genes, with at least 86% 
reads mapping to the mm10 mouse genome.  We identified 16,551 genes and found 
that 324 genes changed significantly between the differentiated and undifferentiated 
states of WT N2a with 180 increasing and 144 decreasing (Fig.2.4E top, Additional File 
2.9-see online). GO analysis revealed that RNAs implicated in cell cycle arrest were 
significantly changed (p-value 4x10-4) under the GO category Biological Process, which 
is expected since undifferentiated cells proliferate in contrast to differentiated cells 
(Additional File 2.9-see online). GO terms in the category Cellular Compartments 
revealed a significant enrichment for RNAs implicated in extracellular region/space and 
neuron projection (Additional file 2.4B).  
To identify Mov10-dependent genes, we compared undifferentiated WT to KO 
and found 813 significantly changed RNAs (300+513) while a comparison of 
differentiated WT to KO showed 781 RNAs (513+268) that were significantly changed 
(Fig.2.4E). 513 genes were shared, suggesting that their expression was regulated by 
Mov10 and independent of differentiation (Additional File 2.10- see online). GO analysis 
of these Mov10 target genes revealed strong clustering with terms relating to nervous 
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system development, axon guidance, and neuron projection with the majority of the 
genes in the groups being down regulated (Fig.2.4F, orange indicates proportion 
significantly downregulated and blue indicates proportion significantly upregulated in the 
KO, see Additional File 2.10 for gene list online). This result suggests a more general 
function for Mov10 as an RNA remodeler in addition to its role in revealing microRNA 
recognition elements (MREs). Similar to its function with Fmrp and Ago2, the fate of the 
mRNA depended on where Mov10 and Fmrp bound in the 3’UTR [2, 25]. The data also 
show that Mov10 expression is critical for neurite outgrowth in N2a cells and is 
consistent with the data from mouse brain, where genes representing cytoskeletal 
components are the predominant functional categories. Additionally, we verified the 
Mov10 dependence of Microtubule-associated protein 1b (Map1b), a cytoskeletal 
protein important in neurite outgrowth [26] and found that it was reproducibly reduced in 
the Mov10 KO and rescued on Mov10 re-expression (Fig.2.4G). Map1b levels went 
down significantly in the KO cells under both differentiated and undifferentiated 
conditions, suggesting that it was a direct target of Mov10 irrespective of the 
differentiation program.  
 To identify the genes regulated by Mov10 that participate in differentiation, we 
compared the 324 (144+180) genes that significantly changed during WT differentiation 
(Fig.2.4E) with Mov10 KO differentiation. There were 64 genes that significantly 
changed in the opposite direction in the differentiated Mov10 KO compared to WT 
(Fig.2.4H). This group of 64 Mov10-dependent, differentiation-specific genes include 
key growth signals such as FGF1 and transcription factors like TEAD2 along with 
cytoskeletal genes such as actin isoforms and Tnnt1 (Additional File 2.9- see online). 
 34 
We appreciate that the RNA-seq data include genes indirectly affected by Mov10 loss 
and are not necessarily directly bound by Mov10, although we do expect there to be 
some direct mRNA targets of Mov10. The direct binding of Mov10 to cytoskeletal 
mRNAs from the RIP and iCLIP data suggest that misregulation of those genes in the 
Mov10 KO leads to reduced neurite outgrowth. In fact some of the same cytoskeletal-
related RNAs are found in both the Mov10-dependent genes in N2a (Additional file 
2.10- see online) and the mouse brain iCLIP lists (Additional Tables 2.7 and 2.11 as 
described in the Methods- see online). We conclude that Mov10 plays a key role in 
neurite development and process formation through its regulation of cytoskeletal and 
neuroregulatory mRNAs. 
Fmrp predominantly binds brain mRNAs that function in neuron projection [27]. 
Because we have evidence that Fmrp and Mov10 functionally associate in HEK293 
cells [2], we examined the effect of Fmrp knockdown on neurite outgrowth in N2a and 
found that it was significantly reduced (Fig. 2.5A). To ask whether Fmrp and Mov10 
functioned in the same pathway, we compared neurite length in the Fmrp/Mov10 double 
knockdown to the Fmrp knockdown alone and found no difference (Fig. 2.5A). This 
result suggests that Fmrp and Mov10 function in the same pathway.  
In earlier work, we showed that when Fmrp and Mov10 bound the same region in 
the 3’UTR of cobound mRNAs, binding by Ago2 was blocked [2]. In this subset of 
mRNAs, Fmrp-Mov10 interaction had a protective effect on the mRNA. To identify 
commonly bound brain mRNA targets of Fmrp, Mov10 and Ago2, we compared the 
iCLIP targets of whole brain-derived Mov10, analyzed as described (Methods and [2], 
Additional File 2.11-see online), which came from postnatal mice (P0, P1). We 
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compared these genes to previously published lists of iCLIP targets from brain-derived 
Fmrp [27], which came from mice aged P11-P25 and iCLIP targets from human brain-
derived Ago2, which came from adult motor cortex and cingulate gyrus from males aged 
44-68 [28] (Fig.2.5B). Despite differences between species and age, we found 
significant overlaps between the Fmrp and Mov10 targets, between the Mov10 and 
Ago2 targets, between the Ago2 and Fmrp targets and between all three proteins.  All 
overlaps were highly significant (p=2.15-19, p=5.57-26 and, p=4.85-159, p=0.00000 
respectively). Using a permutation approach, we also determined that the amounts of 
overlap in the Venn diagram were significantly more than expected by chance 
(Fig.2.5B) (see Methods).  Thus, Fmrp, Mov10 and Ago2 bind a common set of brain 
mRNAs (Additional File 2.12- see online). To understand what the functional 
consequences of such binding might be, we performed GO analysis of the 47 commonly 
bound Mov10-Fmrp-Ago mRNAs and found an enrichment of dendrite, synapse and 
neuron projection terms under the GO category Cellular Compartments (Fig. 2.5C). 
These data suggest a miRNA-mediated function for cytosolic Mov10 in regulating 
cytoskeletal genes. Map1b was one of the genes present in the Fmrp-Mov10-Ago2 
overlap (Fig. 2.5B) and is regulated by Fmrp through the miRNA pathway [29]. Similar 
to the fate described for the Fmrp/Mov10/Ago2-cobound mRNAs in HEK293, Map1b is 
reduced in the absence of Mov10 (Fig. 2.4G), suggesting a protective role for Mov10, 
likely in association with Fmrp.  
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Role of Mov10 in neuronal maturation and behavior 
Because Mov10 is highly expressed in developing brain and is required for 
normal neurite development, we hypothesized that the Mov10 heterozygote mouse 
would show a phenotype. This was the case for the microprocessor component 
DGCR8: loss of both alleles was embryonic lethal but the heterozygotes had a neuronal 
and behavioral phenotype [30-32]. We verified that the Mov10 heterozygote mouse 
(HET) expressed half as much Mov10 in brain (Fig.2.6A) and then examined cultured 
hippocampal neurons from WT and Mov10 heterozygotes (HET). Mov10 heterozygotes 
had markedly less dendritic branching compared to the WT neurons (Fig.2.6B, C). To 
quantify the difference between the Mov10 heterozyote and WT neurons, we performed 
Sholl analysis of all orders of branches (Total Sholl) [33, 34] and observed that a 
reduction in Mov10 levels significantly decreased dendritic branching at a maximum 
distance of 120 µM away from the cell body (*p < 0.05) (Fig. 2.6D).  Thus, normal levels 
of Mov10 are required for normal dendritic arborization.  
To determine whether reduced Mov10 levels affected neuronal function, we 
tested the Mov10 heterozygotes in behavioral tests and found that the Mov10 
heterozygote showed a significant increase in activity in an open-field compared to WT 
littermates (Fig.2.7A), suggesting anxiety and/or hyperactive behavior. The Mov10 
heterozygotes also spent significantly less time in the open arms in an elevated plus 
maze test, suggesting an anxiety phenotype (Fig.2.7B, Additional file 2.5B). In contrast 
we did not see a difference in performance on the rotarod, trace fear conditioning and 
novel object recognition (Additional file 2.5 A,C,D,E). The increased activity in a novel 
environment and increased anxiety seen in the Mov10 heterozygotes suggests that an 
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element of the neuronal circuitry is perturbed in these mice [35]. Thus, WT levels of 
Mov10 are required for normal neuronal development and function.  
 
2.4 Discussion 
We show here two independent and previously undescribed roles for Mov10 in 
embryonic development and postnatal brain. Like the Ago2 knockout, the Mov10 
knockout is also embryonic lethal [36-38] supporting their critical role in miRNA-
mediated regulation during development.  Since Mov10 is present in both the nucleus 
and cytoplasm in neurons, we believe that it is co-opted for critical but distinct functions 
in brain development. We propose that in addition to the cytoplasmic miRNA-mediated 
function of Mov10 in regulating neurite outgrowth in brain, the developmentally timed 
increase of Mov10 acts as a defense against nuclear L1 retrotransposition. 
 
Nuclear Mov10 in LINE-1 suppression 
There is extensive data in cell culture for Mov10’s role in suppressing LINE-1 
retrotransposons [5, 9], although the mechanism is unknown. We present evidence that 
Mov10 directly binds retrotransposon mRNAs in postnatal brain at stages when 
neuronal differentiation is high and acts to inhibit their reverse transcription (Fig 2.2A, 
2.2B) [39]. Significantly, the consequence of reducing Mov10 in brain increases L1 
content in the genome in P2 brains (Fig.2.2C, 2.2D). The mechanism by which Mov10 
inhibits reverse transcription could be by a steric block of ORF2p on L1 mRNA. The L1 
endonuclease and reverse transcriptase ORF2p binds the poly(A) tract of L1 mRNA to 
mobilize it to the insertion site where it nicks the DNA to prime reverse transcription in a 
 38 
3’- 5’ direction [40, 41].  We showed previously that Mov10 binds G-rich regions, 
including G-quadruplexes [2]. Thus, we suspect that Mov10 binds the G-rich 
polypyrimidine tracts [2] present in the 3’UTRs of L1 mRNAs [42] and also interacts with 
ORF2p through it’s N-terminal domain. Subsequently, Mov10 proceeds to unwind in the 
5’-3’ direction causing a steric hindrance to the progress of ORF2p. In support of this 
hypothesis, the helicase-deficient mutant of Mov10 is unable to block reverse 
transcription of L1 mRNAs (Fig.2.2G).  A recent study shows that the G-rich tracts in 
L1s stimulate retrotransposition [43]. We would hypothesize that Mov10 is elevated in 
brain postnatally and localizes to the nucleus to suppress this event.  
 
Mov10 in neurite outgrowth, neuronal development and brain function  
The RNA-IP from postnatal brain also shows a preponderance of actin and cytoskeletal 
mRNAs, suggesting an important role for Mov10 in regulating cytoskeletal dynamics in 
the brain (Fig.2.3). The same observation was made in the RNA–seq analysis from 
Mov10 N2a KO cells further confirming a critical role for Mov10 in neurite outgrowth 
(Fig.4). We hypothesize that this reflects Mov10’s cytoplasmic role in miRNA–mediated 
regulation [2]. It likely plays a role with Fmrp in modulating Ago2 association with 
cobound RNAs (Fig.2.5).         
 Mov10 has low expression in the adult brain (Fig.2.1) similar to what is reported 
in the Allen brain atlas [44, 45]. However, there is no report of Mov10 expression in 
developing brain. We observe an approximately 40-fold increase in Mov10 levels in P0-
P3 mouse brain (Fig.2.1) when events like synaptogenesis, synaptic pruning and 
neuronal differentiation are occurring to shape normal brain circuitry [39]. Mov10 is 
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important for these events since a 50% reduction in Mov10 levels leads to less dendritic 
complexity in hippocampal neurons (Fig.2.6B-D). These data suggest a role for Mov10 
in the normal development of brain circuitry. Based on the evidence that Mov10 
preferentially binds cytoskeletal mRNAs, we hypothesize that the reduction in Mov10 
affects dendritic morphology and synaptic remodeling in the brain. Accordingly the 
Mov10 heterozygote mice show increased activity in a novel environment and higher 
anxiety, suggesting that Mov10 is required for normal brain function (Fig. 2.7A, B).  It is 
also possible that the increased retrotransposition activity in the Mov10 heterozygote 
could be contributing to the neuronal phenotype and behavior. In fact, increased L1 
insertions have been implicated in the development or predisposition to psychiatric 
disorders [46, 47]. 
The cytoarchitecture of neurons has implications in the neuropathology of autism 
and neurodegenerative disorders [48, 49]. In fact CNVs containing Mov10 have been 
found in individuals with developmental delay [50-53]. Our study demonstrates that 
Mov10 is essential in embryonic development, in normal neuronal development and in 
brain function. It remains to be determined how Mov10 levels are regulated in brain. 
 
2.5 Conclusions 
Mov10 is significantly elevated in postnatal murine brain where it binds retroelement 
RNAs and mRNAs. Mov10 suppresses retroelements in the nucleus by directly 
inhibiting cDNA synthesis while cytosolic Mov10 regulates cytoskeletal mRNAs to 
influence neurite outgrowth. Finally, reduced Mov10 in murine brain results in anxiety 
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and increased activity in a novel environment. In summary, Mov10 is essential for 
embryonic viability, normal CNS development and function.   
 
2.6 Methods 
 Western Blot  
Samples from at least three biological replicates were prepared for immunoblotting after 
quantification by Bradford assay and suspension in 1x sample buffer, resolved by SDS-
PAGE and analyzed by western/immuno-blotting. Briefly, membranes were blocked with 
5% non-fat dry milk in PBS containing 1% TWEEN-20 for 1 hour at room temperature.  
Primary antibody was applied for 1hr at room temperature or overnight at 4°C followed 
by a brief wash in 1% non-fat milk PBS containing 1% TWEEN-20 wash buffer.  HRP-
conjugated secondary antibody was applied at 1:5000 dilution for 1 hour at room 
temperature and washed 4x15 minutes using wash buffer.  HRP signal was detected 
using ECL and exposed to film. The antibodies used were anti-Mov10 (Bethyl A301-
571A, RRID: AB-1040002) at 1:1000, anti-Cbx7 (Santa Cruz, sc-70232, 
RRID:AB_2071502) at 1:2000, anti-eIF5 (RRID:AB_631427) (Santa Cruz) at 1:10,000, 
anti-Gapdh (Abcam ab9484, RRID:AB_307274), anti-LINE-1 (Santa Cruz, sc-67198, 
RRID:AB_1249550), HRP-conjugated anti-rabbit and anti-mouse antibodies from GE 
Healthcare (RRID:AB_772191) and Jackson Immunoresearch (RRID:AB_2338512), 
respectively. The level of significance and tests performed are described in the figure 
legends for each experiment.  
Whole mouse brain fixation, sectioning and staining 
Three adult C57BL6 (Envigo, USA {formerly known as ‘Harlan’}) males were euthanized 
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and whole body fixation was done using 4% Paraformaldehyde in PBS. The brain was 
dissected out and fixed with a series of ethanol washes for 30 minutes (25%, 50%, 
70%, 83%, 95% and 100%) and left in methyl salicylate for 3 hours to overnight before 
embedding in paraffin. For P0 and P1 pups, whole, skinned, heads were fixed in 4% 
paraformaldehyde overnight and dehydrated similar to adult brain. Sections were 
prepared using a Spencer 820 rotary microtome and dried overnight at room 
temperature. The sections were de-paraffinized using xylene and rehydrated through a 
series of ethanol washes (100% and 95% followed by 1X PBS) before boiling in 1X 
citrate (pH-6.0) for epitope retrieval. The sections were stained using a primary antibody 
to Mov10 (Abcam ab60132, RRID: AB_944250) at 1:100 and Alexa fluor 596 at 1:800 
(RRID: AB_2340621 Jackson Immunoresearch) before imaging using a Nanozoomer 
Slide Scanner (Hamamtsu) and Zeiss LSM700 Confocal microscope. DAB staining was 
done using the same antibodies and following the instructions in the DAB staining Kit 
(Vector Labs) and counterstained with Hematoxylin before imaging on the Nanozoomer 
Slide Scanner. Testes sections were stained using anti-Mov10 (Bethyl A500-009A, 
RRID: AB_10950563) and anti-mouse-Cy3 (RRID: AB_2340813 Jackson 
Immunoresearch).  
Brain IP, RT-PCR and RNA sequencing 
For the brain-RIP-seq, brains were harvested from 28 WT P2 pups. For confirming 
specific transcripts by brain IP, 3 WT P2 brains were used. All were triturated in HBSS 
and then UV-crosslinked thrice for the confirmatory IP. Triturated cells were lysed in 
Lysis buffer (50mM Tris-Cl 7.5, 300mM NaCl, 30mM EDTA, 0.5% Triton), cleared by 
ultracentrifugation (35000 rpm at 35min at 40C) and sequentially immunoprecipitated 
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with an irrelevant rabbit polyclonal antibody (anti-EGFP, Clontech, RRID: 
AB_10013427) followed by IP with Mov10 antibody (Bethyl A301-571A, RRID: 
AB_1040002). Both IP’s were washed sequentially for 10min with Lysis buffer and twice 
with Wash buffer (1X PBS, 0.1% SDS, 0.5% Sodium deoxycholate, 1% NP40). The IP’s 
were treated with 500 units of RNAse-free DNAse I, washed once for 10min with High 
salt buffer (50mM Tris, 1M NaCl, 1mM EDTA, 1% NP40, 0.1% SDS, 0.5% sodium 
deoxycholate). To isolate associated RNA, the IP’s were treated with proteinase K 
followed by TRIZOL (Ambion) extraction for RNA isolation. The ethanol precipitated 
RNA was quantified and equal amounts were used for cDNA synthesis followed by 
RNaseH treatment.  The RNA was extracted with phenol-chloroform and precipitated in 
ethanol, converted into cDNA using Oligo dT primer and Superscript III Reverse 
Transcriptase. qRT-PCR was performed with iQ SYBR Green Supermix (Bio-Rad) using 
a StepOnePlus RT PCR machine (Applied Biosystems) with gene specific primers. For 
the brain IP-RNA sequencing, WT brains were homogenized in the same manner as 
described above but were not UV crosslinked. Additionally, the Trizol extracted RNA 
was cleaned using an RNA Clean and Concentrator Kit (Zymo Research) before 
sequencing.  
RIP-Seq analysis 
Total input RNA, and RNA extracted from the irrelevant IP and the Mov10 IP were used 
for making libraries and produced over 230 million reads with perfect quality scores. The 
contribution from the irrelevant IP was negligible and removed from further analysis. 
Each fastq file was broken into 100 smaller fastq files using a Perl script downloaded 
from [54]. TopHat2 (version 2.1.1, RRID: SCR_013035) was run on each individual 
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smaller fastq files using –g 2000 and all default parameters. Setting –g 2000 instructs 
TopHat2 to allow up to 2000 alignments to the reference (version mm10 that is not 
masked for repetitive regions, obtained from illumina igenomes) for a given read.  
The resulting alignment files in BAM format were merged into a single BAM file for each 
sample using samtools (version 1.3). BAM files were then sorted based on chromosome 
coordinates of alignments using novosort (novocraft version 3.02; RRID: SCR_014818). 
The total number of reads from the Mov10 IP were 98,884,367, the number of aligned 
reads were 71,522,027 (74.59% aligned), the number of uniquely aligned reads was 
57,005,129 (59.45%). From the input sample, the total number of reads were 
67,566,885, the number of aligned reads were 59,620,379 (88.24% aligned). The 
number of uniquely aligned reads was 29,124,706 (43.11%).  To identify protein-
associated transcripts, a Bioconductor based statistical package RIPSeeker was used 
[13]. RIPSeeker’s  (version 3.3; RRID: SCR_006810) function ripSeek was run using 
the alignments generated by TopHat2 with parameters:uniqueHit=TRUE, 
assignMultihits=TRUE, rerunWithDisambiguatedMultihits=TRUE, and binSize=NULL. 
Setting uniqueHit=TRUE requires training Hidden Markov Model (HMM) with only the 
unique hits, assignMultihits=TRUE enables function disambiguateMultihits to assign 
each multihit to a unique locus based on the posterior probabilities derived from HMM, 
rerunWithDisambiguatedMultihits = TRUE tells RIPSeeker to retrain the HMM using the 
dataset with disambiguated multihits, binSize = NULL enables automatic bin size 
selection. ripSeek function was run separately for plus strand and minus strand and the 
output files in GFF3 format were combined into a single GFF3 file that contains genomic 
coordinates for all the regions identified to be significantly enriched in Mov10 IP 
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compared to Input. To identify repeat elements and transcripts that overlap with RIP 
regions identified by RIPSeeker, two tab delimited text files were downloaded from 
UCSC Genome browser’s table browser interface. One text file contains genomic 
coordinates of all repeat elements on mouse reference genome mm10 extracted from 
repeat masker database and another text file contains genomic coordinates of all 
mouse transcripts on mouse reference genome mm10 extracted from NCBI RefSeq 
database (RRID: SCR_003496).  Bedtools intersect (version 2.25.0) was run to identify 
repeat elements and mouse transcripts that overlap with RIP regions.  2996 RIP peaks 
were identified: 1313 overlapped with repeat elements from the repeat masker database 
and 1683 peaks had no overlaps with repeat masker with 755 peaks overlapping with 
RefSeq.  
 
Mouse brain iCLIP analyses 
16 brains from P0 and P1 mice were triturated in HBSS and UV-cross-linked three times 
(Stratalinker) with mixing between treatments. A published iCLIP protocol was followed 
[55, 56]. The irrelevant IP was performed with a rabbit affinity purified antibody EGFP 
(Clontech, RRID: AB_10013427) The Mov10 IP was performed with antibody (Bethyl 
A301-571A, RRID: AB_1040002). Mov10-CLIP libraries were sequenced by the UIUC 
sequencing core facility using the Illumina HiSeq2000 platform. The fastq data was 
trimmed using Trimmomatic (version 0.30, RRID: SCR_011848) to (1st) trim off (crop) 
the last 14 nucleotides from all the reads, (2nd) trim nucleotides with a quality value 
lower than 20, from the far (3’ end) of the read, (3rd) trim nucleotides with a quality value 
lower than 25 from the 5’ end of the read, (4th) remove the adaptor/known contaminant. 
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Reads with 30 or more nucleotides remaining after the trimming were kept. This data, 
processed as described below, is presented in Additional File 2.7. Reads with 18 or 
more nucleotides remaining after the additional trimming were kept and processed as 
described below. The genes identified are in Additional File 2.11 and were used in the 
comparisons in Figure 5. The fastq files were converted to fasta files, which were 
compressed to eliminate duplications, based on the tags. The compressed fasta file of 
tags was then separated into 2 files—representing the irrelevant and Mov10 
immunoprecipitations—each file containing the tags with a specific barcode. This step 
utilized scripts that did the separation and also removed the barcode from the read, in 
preparation for the alignment step. The separated samples were aligned to the mouse 
genome (mm10) using Novoalign (RRID: SCR_014818). The only parameter specified 
was “-t 60”, this allows for 2 mismatches between the genome and the read. Uniquely 
mapping reads were extracted from the resulting sam files and the information was 
converted to bam format using samtools (samtools view; RRID: SCR_002105). The 
bam format was converted to bed (genome interval) format using bedtools (version 
2.17.0; RRID: SCR_006646) (bamToBed). The genome intervals of the reads (bed file) 
for each sample were merged into larger intervals using bedtools (mergeBed). The new 
interval/region is a location with a set of overlapping reads. Any regions that had any 
presence in the control Irrelevant samples (intersectBed) were removed to give the final 
set of experimental genome intervals that have reads mapping to them in the Mov10 
immunoprecipitations, which will be referred to as “Regions” from here on.  IntersectBed 
(bedtools) was used to determine which regions overlap with genes, exons, UTRs, 
lncRNAs (Ensembl) regions using bed files specific for these features respectively.  All 
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regions that overlap with genes, but not with exons are considered intronic, and all other 
regions are considered intergenic.. DAVID 6.8 analysis [57, 58] (RRID:SCR_001881) 
was performed on the Mov10 CLIP targets using a P1 C57Bl/6 brain background (GEO 
numbers GSM417923, GSM417922, GSM417921) 
In-vitro reverse transcriptase assays 
Total RNA from three P2 mice brains was used in the reverse transcription assay with 
either Superscript III Reverse Transcriptase (Invitrogen ThermoScientific, Carlsbad, CA) 
alone or with equimolar amounts of recombinant Mov10 or FMRP [2] after pre-
incubating the proteins on ice for 5min. cDNA synthesis was carried out at 500 c for 
45min, 700 c for 15min. RT-PCR reactions was carried out on the cDNA samples using 
primers to Prrc2b, mL1TF or Gapdh (Additional File 14). For q-RT-PCR, iQ SYBR Green 
Supermix (Bio-Rad) was used and the reactions were set up in a StepOnePlus RT PCR 
machine (Applied Biosystems) with gene specific primers. 
Purification of the C-term, N-term and Mov10 helicase mutant 
The Myc-tagged Mov10 helicase mutant was generated using site-directed mutagenesis 
to mutate the conserved lysine in Motif I to Alanine (K531A). The HA-tagged N-terminal 
half and C-terminal half plasmids was obtained from [23]. Constructs were transfected 
using PEI (polyethylenimine, # 408727, Sigma) in Freestyle HEK 293F cells (Invitrogen) 
and cultured according to the manufacturer’s protocol and as described [2]. The cells 
were harvested after 48 hours and lysed in Lysis buffer (50mM Tris-Cl 7.5, 150mM 
NaCl, 30mM EDTA, 0.5% Triton) containing Protease inhibitors (Roche, Indianapolis, 
IN) and spun at 14000 rpm for 5min at 4°C. The supernatant was immunoprecipitated 
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with anti-HA Magnetic beads (Thermo Fisher Scientific, Carlsbad,CA) for the HA tagged 
C-term and N-term Mov10 and peptide eluted with HA peptide (2 mg/ml, Protein 
Sciences, Roy J Carver Biotech Center, UIUC) for 2 hours at 4°C. The Mov10 helicase 
mutant was immunoprecipitated using agarose beads coupled to myc antibody (RRID: 
AB_10109522, Sigma-Aldrich, St. Louis, MO) and peptide eluted using the myc peptide 
(2 mg/ml, Protein Sciences, Roy J Carver Biotech Center, UIUC). Protein 
concentrations were calculated using Bradford Assay (Bio-rad Laboratories, Hercules, 
CA) and visualized on silver stain. 
 
Protein Binding Assay 
For testing direct binding of recombinant WT and helicase deficient Mov10 and SSRTIII, 
5ug of BSA or SSRTIII were coupled to M270-epoxy Dynabeads (Life Technologies) 
overnight at 40C. The protein-coated beads were washed according to the 
manufacturers protocol and 10ul of beads (2.5ug protein) was used in a reaction with 
equimolar amounts of recombinant Mov10 in three independent trials. The reactions 
were incubated on ice for 30min and washed in 1X PBS. The samples were 
subsequently processed for Western blotting with the Mov10-specific antibody. 
Genomic DNA isolation and qRT-PCR 
Brains were dissected from three separate WT and Mov10 heterozygote mice and total 
genomic DNA was isolated using the DNAzol reagent (Invitrogen). The DNA was 
ethanol precipitated and treated with ExonucleaseI (NEB, Ipswitch, MA) or RNAse H 
(NEB) as per the manufacturer’s protocol. Equal amounts were used in quantitative RT-
PCR using primers for ORF2 and 5S rDNA to estimate total LINE-1 content (see 
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Additional File 2.14). 
N2a transfection, neurite analysis and preparation for RNA sequencing 
N2a wild type (RRID: CVCL_0470) and Mov10 KO clones were plated in triplicate at a 
density of 1.5x104 cells per well and incubated for 24 hours at 37o C in DMEM (with 
10% FCS). One set of the Mov10 ko wells were transfected using Lipofectamine 2000 
(Thermo Fisher Scientific) with a plasmid bearing full-length mouse Mov10 before 
differentiating with DMEM (2% FCS) and 20uM Retinoic Acid (Sigma-Aldrich) a day 
later. Cell were allowed to differentiate for 48 hours and imaged under transmitted light 
using an EVOS cell-imaging microscope. The images were anonymized and analyzed 
by an experimenter blinded to the conditions using the Axiovision Image analysis 
software. 500-800 differentiated neurons were counted from triplicate experiments and 
a total of 11 images were counted per condition. 
For total RNA sequencing, 2x105 cells were plated in a 6-well plate and 
differentiated using 2% FCS and Retinoic Acid after 24hrs. The cells were allowed to 
differentiate for 48hrs with a media change every 24hrs. Total RNA was isolated using 
TRIZOL reagent (Ambion) and the RNA quality was checked on a 1% MOPS-Agarose 
gel. The samples were DNAse treated and cleaned and concentrated using the RNA 
clean and concentrator Kit (Zymo Research) before sequencing. 
RNA-seq analysis of N2A 
  The llumina HiSeq4000 sequencer was used in paired-end mode.  Library adapters 
were trimmed and reads were mapped to the Encode mm10 genome using STAR in 
paired-end mode [59].  Each sample produced ~350,000,000 million paired reads 100bp 
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in length.  These reads mapped to the genome with >85% coverage.  CuffDiff was used 
to identify differential expression between experimental groups [60].  Cuffdiff results 
were further filtered by P-value (< .005), expression levels (one or both conditions 
contains the gene at > 1 FPKM), and fold change (log2 (fold change) > 1).  RRID 
numbers for the software:  Cuffdiff: SCR_001647; CummeRbund: SCR_014568; 
DAVID: SCR_001881; Cytoscape: SCR_003032 
GO analysis 
Gene lists generated from RNA-seq analysis were analyzed for patterns in gene 
ontology using DAVID 6.8 [57, 58].  An enrichment map of significant ontology terms 
was generated using the Cytoscape Plugin EnrichmentMaps [61, 62].   
 
CRISPR-Cas9 knockdown in N2a cells 
Guide RNAs (Additional File 2.14) were designed to the mouse Mov10 locus as 
described in [63] and cloned into pX459 plasmid (Addgene). Constructs were 
transfected into WT N2a, serially diluted into 96-well plates and grown under Puromycin 
(2ug /ml) selection. Puromycin-resistant colonies were selected and screened for 
Mov10 expression using Western Blot analysis and confirmed by sequencing. 
Nuclei purification and fractionation 
WT brain tissue was extracted from three P2 mice and nuclei preparation was done as 
described in [64]. 100 mg of the tissue was minced and the nuclei extracted using a 
nuclei isolation kit (Sigma NUC201), separated by ultracentrifugation at 40,000 rpm for 
30min at 40C (Beckman TL-100). Nuclei were suspended in CSK buffer containing 
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10mM PIPES, 300mM sucrose, 1mM EGTA, 200mM NaCl, 1mM DTT and Roche 
protease inhibitor cocktail. The separated nuclei containing CSK buffers were 
supplemented with 1mM PMSF, left at 40 C for five minutes, centrifuged at 2000xg for 
five minutes at 40C to separate the nucleoplasmic and chromatin fractions.  
Hippocampal neuron culture 
Mov10 heterozygotes were genotyped at P0 using tail samples and DNA was extracted 
with KAPA Fast Extract Kit (KAPA Biosystems # KK7103). After genotyping, mouse 
hippocampi were dissected and cultured on embryonic day 20 (E20), or postnatal day 0 
(P0), as described [65]. Coverslips were coated overnight with Poly-L-lysine (Sigma, 
P4707, 10ug/mL) and 105 cells/well were plated for immunofluorescence (IF) in 
minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS). 
After 24 hours, medium was switched to Neurobasal (NB) medium (Gibco, 21103049) 
supplemented with B-27 (Gibco, 17504-044). Half of the media was removed and 
replaced with fresh NB medium every 3 days. 
Immunofluorescence and microscopy of cultured neurons 
Neurons grown on coverslips were fixed in 4% paraformaldehyde for 10 minutes at 
room temperature, either 24 hours after initial culture (DIV0) or 14 days later (DIV14). 
Samples were blocked in 10% normal donkey serum (Jackson ImmunoResearch, 017-
000-121) for 30 minutes at room temperature. Mov10 primary rabbit polyclonal antibody 
(1:1000, Bethyl, A301-571A RRID: AB_1040002) or MAP2 antibody (1:1000 dilution, 
Millipore # AB5622, RRID: AB_91939) were incubated overnight at 4°C. Secondary 
antibody (Alexa 594 goat anti-rabbit {1:4000, Jackson ImmunoResearch, 111-585-144, 
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RRID:AB_2307325}) was added for 2 hours, room temperature. Coverslips were 
inverted unto glass slides containing mounting media with 1ug/mL 4', 6-diamidino-2-
phenylindole (DAPI). Fluorescence images of DIV0 and DIV14 neurons were obtained 
with a Zeiss LSM 700 inverted confocal microscope using a 40x and 63x EC Plan-
Neufluar 1.30 oil objective respectively. Images were captured with a cooled CCD 
camera running Zen 2012 software. A total of 10-15 0.2 µM thick section were acquired 
as z-stacks for each time point.  
Sholl analysis 
Sholl analysis of all orders of branches (Total Sholl) was performed. Confocal z-stacks 
of either WT or Mov10 heterozygous DIV 14 neurons immunostained for MAP2 were 
imported into ImageJ. Dendritic complexity, including Sholl analysis, was performed 
according to the protocol described [33].  
 
Behavior tests 
 The sample size for behavioral testing was estimated using G* power [66] from a pilot 
study using 5 animals. The analysis recommended a sample size of 4 animals per 
group and showed an effect size d= 2.522797 and a power of 0.842302. We decided to 
use at least 10-15 animals per group to account for attrition and outliers. We excluded 
outliers based on z-test cutoff of  +/- 2 Standard Deviations from the mean. 60-65 day 
old mice were tested at the same hour of the day in the following sequence: open field, 
novel object recognition, rotarod, elevated plus maze and trace fear conditioning. The 
experimenter was blinded to the genotypes. Both sexes were tested on the rotarod, 
elevated plus maze and trace fear conditioning.  
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Open-field test-The test was performed on the first day of the novel object recognition 
test. Mice were exposed for 5 min to a rectangular arena (46x25x20 cm) and the 
distance covered was tracked using a Logitech HD Pro webcam. The videos were then 
analyzed using the TopScan LITE software (Cleversys Inc., Reston, VA, USA). 
Novel object recognition - The test was performed as described [67]. Briefly, mice were 
habituated to the empty arena on the first day for 5 min. After 24 hours, two similar 
objects were presented and the interaction with each object was tracked using a 
webcam. The pair of objects used in the test was randomized between animals. On day 
3, a novel object replaced one of the objects and the mice were video-tracked. The 
placement of the novel object was randomized between animals. The videos were 
analyzed using the ObjectScan software (Cleversys Inc.) to estimate interaction times. 
Rotarod - Mice were placed on a stationary rotarod (AccuRotor Rota Rod Tall Unit, 63-
cm fall height, 30-mm diameter rotating dowel; Accuscan, Columbus, OH, USA). The 
dowel was then accelerated at 60 rpm/min, and the latency to fall (in seconds) was 
recorded. The procedure was repeated for 4 consecutive trials, which were averaged to 
give the daily latency to fall for each mouse. The trials were repeated for 2 more days 
for a total of 3 days. 
Elevated plus maze – The apparatus consists of four arms (66cm x 6.4cm), an open 
area in the center (6.4 cm), two opposing open arms and two opposing closed arms 
(20cm high wall) with sliding doors at the end. The maze is elevated at a height of 60cm 
from the floor. Mice were placed in the center of the maze and the time spent in each 
zone was recorded for 10 min using the webcam. The TopScan LITE software analyzed 
the videos. 
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Trace fear Conditioning – A modified procedure of the test was performed as described 
[68]. Mice were trained by exposing them for 3 min to a chamber (34x 28x30 cm) where 
they received three consecutive pairs of tone (10s) and shock (0.5mA, 1s) with an 
empty trace interval of 1s and a 3 min break between each tone-shock pairing. Behavior 
was recorded using a webcam in a new context with the same tone but without shock 
48 hours after training (trace fear conditioning). Five days after training, the mice were 
placed back in the original training chamber without tone or shock and recorded for 6 
min (context conditioning). The videos were analyzed using TopScan LITE to measure 
the level of freezing in both cases.  
Venn Diagram for Mov10/Fmrp/Ago2 overlaps 
842 genes with Fmrp-CLIP sites from [27] contained NCBI’s Entrez Gene IDs in the 
Supplementary Table. All but two of the IDs were in the current Bioconductor 
org.Mm.eg.db database (v 3.4.0) (RRID: SCR_006442). According to NCBI, these two 
IDs were replaced with different IDs, so we used the updated IDs. Mouse gene symbols 
for the 842 Entrez IDs were pulled from org.Mm.eg.db. Human genes with Ago2 binding 
sites were taken from Suppl. Table 3 [28]. There were 7,153 binding sites in 3,416 
unique Ensembl Gene IDs. Ensembl Gene IDs were converted to Entrez Gene IDs 
using the current Bioconductor org.Hs.eg.db database (v 3.4.0); 3,173 Ensembl IDs had 
perfect 1:1 matches with Entrez IDs. 150 genes had no matches based on Ensembl ID, 
but we were able to assign Entrez IDs for 109 of them using the Gene Symbol or 
RefSeq ID listed in Suppl. Table 3. 93 genes had more than one Entrez ID listed for the 
Ensembl ID, however many of the EntrezID were for miRNA, and 57 genes matched to 
a single mRNA Entrez ID; an additional 33 genes were matched to a single EntrezID 
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using the Gene Symbol or RefSeq ID from Suppl. Table 3. We were left with 3,372 
unique Ensembl genes, although a few of these were assigned the same Entrez ID, so 
there were 3,335 unique Entrez Gene IDs that had Ago2 binding sites. Human gene 
symbols for these Entrez IDs were pulled from org.Hs.eg.db. 
Mouse genes with Mov10 binding sites were taken from Additional File 2.11. There 
were a total of 930 binding sites, although 252 of these were in intergenic/intronic 
regions and were not assigned to a gene. An additional 2 sites were assigned to two 
different genes and these were removed. The remaining sites were in 539 unique, 
current Entrez Gene IDs. Mouse gene symbols for the 539 Entrez IDs were pulled from 
org.Mm.eg.db. While database IDs like Entrez Gene or Ensembl are much more stable 
over time than gene symbols, they are species-specific and hence cannot be used to 
easily map between species. Instead, both human and mouse use similar nomenclature 
systems for gene symbols, such that gene symbols from different databases at the 
same point in time should be comparable. The main difference is in capitalization, so 
symbols were matched by converting both to all capital letters. While only using genes 
with identical symbols between human and mouse will miss some true homologs, it 
simplifies the comparison by removing any many-to-one or many-to-many relationships 
that would be impossible to assess statistically.  The two Bioconductor databases from 
the same release, org.Hs.eg.db_3.4.0 and org.Mm.eg.db_3.4.0, share 16,760 gene 
symbols in common. This gene set was used as the background to assess whether 
Fmrp, Ago2 and Mov10 tend to have binding sites in the same genes. After removing 
genes not in the background, we compared 821 Fmrp genes, 3,130 Ago2 genes and 
502 Mov10 genes for overlaps (Figure 2.5B). First, we compared the pairwise overlaps 
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using a one-sided Fisher’s exact test and all 3 sets were highly significant (Fmrp & 
Mov10, 77 genes in common, p = 2.15e-19, Fmrp & Ago2, 490 genes in common, p = 
4.85e-159, Mov10 & Ago2, 193 in common, p = 5.57e-26). If we test the pairwise 
overlap between Fmrp and Mov10 using the full mouse background of 23,294 genes, 
their overlap of 80 genes is even more significant (p = 2.50e-27), indicating that the 
common background is actually more conservative. We also used a permutation 
approach to test whether the amounts of overlap in the Venn diagram were more than 
expected by chance by randomly selecting gene sets of 821, 3,130 and 502 from the 
16,760 background and counting the numbers of genes in common. We repeated this 
50,000 times and used the resulting distributions of overlap values to empirically derive 
one-tailed p-values for our four observed overlaps: 1) Fmrp and Mov10 only (30 genes), 
2) Fmrp and Ago2 only, (443 genes), 3) Mov10 and Ago2 only (146 genes) and 4) all 3 
binding sites (47 genes). The Fmrp and Mov10 only overlap, had a p-value = 0.01116, 
which while significant is not nearly as significant as the other three overlap gene sets, 
which all had p = 0, meaning a larger overlap was not seen in 50,000 random 
samplings. R version 3.3.3 (R project for statistical Computing-RRID: SCR_001905), 
using a custom script to randomly pull out subsets of genes of the correct sizes and 
count overlaps was used.  
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2.7 Figures and tables 
 
Table 2.1 
Number of pups from heterozygote mating 
Wild type Heterozygous Homozygous Total 
44 (28%) 112 (72%) 0 (0%) 156 (100%) 
 
Screening of embryos from E9.5 
Wild type Heterozygous Homozygous Total 
5 (36%) 9 (64%) 0 (0%) 14 (100%) 
 
Screening of embryos from E12.5 
Wild type Heterozygous Homozygous Total 
0 (0%) 21 (100%) 0 (0%) 21 (100%) 
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Figure 2.1. Mov10 is significantly elevated in young mouse brain and is both 
nuclear and cytoplasmic. A) Brain extract (25ug) from C57BL/6 at ages indicated was 
immunoblotted for Mov10 and eIF5α as a loading control (top panel). Bar graph of the 
three independent experiments is shown in the bottom panel. Spearman’s rank-order 
correlation (ρ (70)= -0.371, ***p=0.001). B and C) 3-3’ Diaminobenzidine (DAB) stain of 
P1 brain (sagittal section) and counterstained with Hematoxylin.   
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Figure 2.1 (cont.) - CTX-cortex, HC-hippocampus, CB-cerebellum, HB-hindbrain, MB-
midbrain. (B) No primary antibody; (C) Mov10 antibody. Images obtained using the 
Hamamatsu Nanozoomer slide scanning system. Scale bar= 1mm D-I) Mov10 
immunohistochemistry of P2 brain (D, E, F) and adult hippocampus (G, H, I) Scale bar = 
10um. 
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Figure 2.2. Mov10 binds repeat element RNA and mRNA in P2 brain and blocks 
retrotransposition. A) Results of RNA-IP followed by sequencing. Left pie-chart shows 
the distribution of all immunoprecipitated RNAs. Right pie-chart shows the classification 
of the repeat elements.  
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Figure 2.2 (cont.) - B) RT-PCR of Mov10 or Irrelevant (IRR) IP from P2 brains for 
Mov10 iCLIP target mRNA (Prrc2b) and an active mouse L1 RNA (mL1TF) and for the 
mRNA Grin2A, which does not bind Mov10 [9]. C, D) q-PCR of DNAse I and RNAse H 
treated genomic DNA isolated from P3 heterozygote (HET) or WT littermate brain (n=3) 
amplified with ORF2 primers and 5S rDNA for normalization. Values plotted relative to 
adult genomic DNA content.  Error bars represent SEM,  *p <0.05 (Student’s t-test, two-
tailed). E) Representative gel images of the reverse transcriptase assay set up as 
shown in the table, SSRTIII was preincubated with the indicated concentrations of 
purified Mov10 or human purified recombinant FMRP as a control, followed by RT-PCR 
of RNAs bound by Mov10 (Prrc2b or L1TF) or not (Gapdh). F) RT-qPCR of Prrc2b, 
mL1TF and Gapdh with indicated ratios of Mov10 and SSRTIII.  Biological replicates are 
shown and the fold change was compared to the RT-only reaction of each gene. Error 
bars represent SD,  *p <0.05 (Student’s t-test, two-tailed). G) Representative gel images 
for the RT assay using equimolar amounts of the Mov10 helicase-deficient mutant and 
SSRTIII. H) Capture assay with WT, C-terminal and N-terminal of Mov10 and reverse 
transcriptase (SSRT III) or BSA covalently coupled to beads. I) Mov10 or irrelevant 
(IRR) IP from P2 brains immunoblotted for L1-ORF2 (representative image of n=3). The 
averages from biological replicates of the ratio between ORF2 and Mov10 for each lane 
are indicated below, the P-values of which are not significant. 
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Figure 2.3. Mov10 binds mRNAs encoding proteins involved in neuron projection 
and cytoskeleton by RIP, iCLIP.  
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Figure 2.3 (cont.) - A) GO analysis of RIP mRNAs from postnatal brain. Y axis-GO 
terms-Cellular Compartment; X axis- negative log (base 10) of the ten lowest P values 
(See Additional file 2.5). B) GO analysis of iCLIP mRNAs from postnatal brain. Y axis- 
GO terms for Cellular Compartment and Molecular function; X axis- negative log (base 
10) of the P values, only showing terms with p-values of 10-6 or lower. (Right) 
Autoradiograph of Irr and Mov10 IP from P0/P1 brains from iCLIP (See Additional file 
2.7).  
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Figure 2.4. Mov10 is required for neurite outgrowth and neuronal morphology.  
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Figure 2.4 (cont.) - A-C) Brightfield images of N2a (WT), Mov10 knockout N2a (KO) 
and Mov10 transgene rescue of KO (Rescue). Scale bar represents 200um. D) 
Quantification of neurite length of WT, KO and rescue, analyzed by one-way ANOVA (F 
(2,19) = 32, p=0.000, p-values, ** 0.03, *** 1.60484E-06).  Error bars represent SEM.  
500-800 differentiated neurons were counted from triplicate experiments and a total of 
11 images were counted per condition. Lower panel is Mov10 immunoblot of WT, KO 
and Rescue; eIF5α is loading control. E) Schematic of significantly changed genes 
between WT undifferentiated and differentiated N2a. The number of differentially 
expressed genes as determined by CuffDiff (p-value < .005 and FPKM > 1) under both 
conditions is displayed (top). Venn diagram of genes differentially expressed in the KO 
versus WT. Orange (813)- genes identified from comparison between undifferentiated 
WT and KO; Green (781)- genes identified from comparison between differentiated WT 
and KO; Purple (513)- Mov10-regulated genes (bottom). F) Enrichment map of top 
Gene Ontology terms for the 513 Mov10 regulated genes (DAVID, p value < 0.025) 
showing enrichment for genes related to nervous system development, axon guidance, 
and neuron projection. Fraction of genes up (blue) and down (orange) regulated in KO 
cells. G) Map1b immunoblot from WT, Mov10 KO and rescue. Gapdh is the loading 
control. H) Significantly changed genes between WT differentiated and undifferentiated 
(324). 64 of those genes significantly changed in the opposite direction of WT in the KO. 
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Figure 2.5. Mov10, Fmrp and Ago2 bind mRNAs enriched for neuronal genes. A) 
Top panel shows graph of mean neurite lengths between WT N2a cells treated with Irr 
siRNA, Fmr1 siRNA and Mov10 KO N2a cells treated with Fmr1 siRNA (n=3) Error bars 
represent SEM. Statistic- one-way ANOVA, (F (2,64)=28, p<0.001, p-values = *** 
6.01E-06, NS= 0.13). Bottom panel shows a representative Fmrp western blot of the 
three conditions. eIF5α is the loading control.  
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Figure 2.5 (cont.) - B) Venn diagram showing the overlap between brain-derived iCLIP 
targets of Fmrp, Mov10 and Ago2. All three proteins in brain commonly bound 47 
mRNAs and the overlap was highly significant (see Methods). C) GO analysis of the 47 
overlapped genes from panel B. Y-axis is GO terms for Cellular Compartment and the 
X-axis is the negative log10 of the P-values (see Additional file 2.12). 
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Figure 2.6. Normal levels of Mov10 are required for normal neuronal morphology. 
A) 25ug of total brain extract from P2 mice (genotypes shown above: HET is the Mov10 
heterozygote, missing one copy of Mov10) immunoblotted for Mov10 and eIF5α. 
Immunoblot quantification (n=3), Error bars represent SD, *p <0.05 (Student’s t-test, 
two-tailed). B and C) Map2 immunostaining of hippocampal neurons from DIV14 WT 
(B) and Mov10 heterozygous (C) neurons. D) Dendritic morphology analysis. Confocal 
z-stacks of Map2-stained WT or Mov10 heterozygote DIV 14 neurons were analyzed 
using Sholl. Statistics were calculated using Two-Way ANOVA followed by Bonferroni 
multiple comparisons test. Error bars indicate SEM and *p < 0.05. (n = 56 neurons for 
WT, and n = 94 neurons for Mov10 HET).  
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Figure 2.7. Normal levels of Mov10 are required for normal behavior. A) Activity in 
an open field of WT and Mov10 heterozygous (HET) littermates (n=17) plotted as 
Distance travelled (mm). Error bars represent SEM, *p< 0.05 compared to WT 
(Student’s t-test, two-tailed). B) Percent time spent in open arms in the elevated plus 
maze by WT and Mov10 heterozygotes (n=10). Both sexes were used because no 
significant difference was observed between sexes (WT, p 0.71, Mov10 HET, p 0.33; 
Student’s t-test, two-tailed). Error bars represent SEM and *p <0.05 compared to WT 
(Student’s t-test, two-tailed). 
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Additional file 2.1. Mov10 levels are elevated in FVB mice and are independent of 
sex. A) FVB brain (25ug) at ages indicated, immunoblotted for Mov10 and eIF5α 
(loading control). Quantification of three independent experiments performed as shown 
below. Error bars represent SD and P-value indicates **p<0.01 compared to adult. 
B) Top panel- 25ug of P0 brains from 2 male and 2 female mice were immunoblotted for 
Mov10. 25ug of adult brain lysate was used for comparison. Bottom panel- Genomic 
DNA was isolated from the P2 brain lysates of each mouse and PCR was performed 
using SRY primers. Actin was used as a PCR control. 
 70 
 
 
Additional file 2.2. Mov10 is nuclear in P0 cortex and hippocampal cultures 
compared to adult. 
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Additional file 2.2 (cont.) - A) DAB staining of P0 (left) and adult hippocampi (right) 
with Mov10. Inset shows the cellular localization of Mov10. Images obtained using the 
Hamamatsu Nanozoomer slide scanner. Scale bar = 250um. B) Immunofluorescence 
staining of Mov10 in P0 (left) and adult (right) cortex. Images obtained using the 
Nanozoomer slide scanning system. Scale bar = 100um. C) Immunofluorescence of 
endogenous Mov10 (red) at DIV1 (top panel), and DIV14 (bottom panel) in cultured 
primary hippocampal neurons. Nuclei were visualized with 4’, 6-diamidino-2-
phenylindole (DAPI). Scale bar = 20 um for top panel and 10um for bottom panel. D) 
Immunohistochemistry of Mov10 in mouse testes sections from a WT male. Scale bar = 
20um. E) Representative immunoblot from the nuclear fractionation of P2 brain (n=3). 
25ug of purified nuclei preparations and cytoplasmic lysate was loaded and the 
proportion of Mov10 in the Supernatant (S) and Pellet (P) were determined using 
immunoblotting. TFIID and Histone were used as controls for fractionation. 
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Additional file 2.3. Schematic of gene trap insertion into murine Mov10 gene to 
generate a knockout allele. Domain structure of Mov10 corresponding to exon 
sequence of murine Mov10 (NM_008619.2). Exons are shown as black vertical lines 
and the gene trap vector is shown as inserting (red arrow) 3’ of start (ATG) in that exon. 
The resulting targeted allele is shown at the bottom. Gene trapping strategy is described 
[111]. C57BL/6 ES cell (Clone IST13267G7sE6, RRID:IMSR_TIGM:IST13267G7) from 
the Texas Institute of Genomic Medicine (TIGM) was used to generate the Mov10 
heterozygote.  
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Additional file 2.4. Mov10 binds mRNAs involved in actin cytoskeleton by RNA-
seq. A) Screen shot from the sequencing of Mov10 exon2 in Mov10 KO N2A clone. Top 
panel is from WT Neuro2a. The bottom panel shows the mutant clone with the insertion 
generated by CRISPR-Cas9 mediated gene targeting. The mutation is boxed out. 
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Additional file 2.4 (cont.) - B) Gene ontology analysis for Cellular compartments from 
undifferentiated and differentiated WT Neuro2a. (See Additional File 9 online) 
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Additional file 2.5. Behavior testing of Mov10 heterozygotes. A) Rotarod testing 
was performed on both WT and Mov10 heterozygous littermates (HET) of both sexes 
(n=11). No significant difference was found between sexes (WT, p = 0.44, Mov10 HET, 
p=0.81; Student t-test, two-tailed). Latency to fall (millisecond) was calculated by 
averaging four trials per animal over 3 days. Error bars represent SEM. B) WT and 
Mov10 HETs (n=10) of both sexes were used in the elevated plus maze and the percent 
time spent in the open and closed arms are plotted. Error bars represent SEM.  
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Additionale file 2.5 (cont.) - C) Trace fear conditioning memory test- the level of 
freezing (percentage) in a new context with tone was assessed for WT and Mov10 
HETs (n=11). Both sexes were tested and no significant difference was found (WT, 
p=0.33, Mov10 Het, p=0.34; Student t-test, two-tailed). Error bars represent SEM. D) 
Context fear memory test. The level of freezing (percentage) was measured on re-
exposure to training context and is plotted for both WT and Mov10 HETs (n=11). Both 
sexes were tested and no significant difference was found (WT, p=0.97, Mov10 Het, 
p=0.38; Student t-test, two-tailed). Error bars represent SEM. E) Percent novelty 
preference was calculated from interaction times {100x (time spent with novel object/ 
time spent with both objects} and is plotted for WT (n=10) and Mov10 HET (n=12) 
males in the novel object recognition test. Error bars represent SEM. Student t-test, 
one-tailed. 
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CHAPTER 3 
RNA HELICASE MOV10 IS ESSENTIAL FOR GASTRULATION AND CNS 
DEVELOPMENT 
(This work has been submitted to Developmental Dynamics) 
 
3.1 Abstract   
Background: Mov10 is an RNA helicase that modulates access of Argonaute 2 to 
microRNA recognition elements in mRNAs. We examined the role of Mov10 in Xenopus 
laevis development and show a critical role for Mov10 in gastrulation and in the central 
nervous system during embryonic and postnatal development. Results: Knockdown of 
maternal Mov10 in Xenopus embryos using a translation blocking morpholino led to 
gastrulation defects, failed convergent extension and a failure to neurulate. RNA 
sequencing of the Mov10 knockout embryos showed significant upregulation of mRNAs 
compared to controls at Stage 10.5. Additionally, the degradation of the miR-427 target 
mRNA, cyclin A1, was affected in the Mov10 knockouts. These defects suggest that 
Mov10’s role in miRNA-mediated regulation of the maternal to zygotic transition could 
lead to pleiotropic effects that cause the gastrulation defect. Additionally, the knockdown 
of zygotic Mov10 showed that it was necessary for normal head, eye and brain 
development in Xenopus consistent with a recent study in mouse. Conclusions: Mov10 
is essential for gastrulation and normal CNS development and function. 
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3.2 Introduction 
The RNA helicase Mov10 was originally described as a cofactor for RNA-induced 
silencing complex (RISC) component Argonaute 2 (Ago2) that was required for 
microRNA (miRNA)-guided cleavage of a reporter [1]. Mov10 binds to G-rich secondary 
structures in mRNAs and unwinds RNA in a 5’-3’ direction in an ATP-dependent manner 
[2, 3]. Mov10 also associates with nonsense-mediated decay factor UPF1 [2]. In 
addition, Mov10 suppresses viral RNAs and retrotransposition in cultured cells [4, 5] We 
recently showed that Mov10 is required during embryonic development because the 
Mov10 knock out mouse is embryonic lethal; however, we were unable to identify the 
early developmental defects associated with this lethality [6]. 
Here, we demonstrate a conserved role for Mov10 during embryonic 
development in Xenopus laevis.  Blocking translation of maternal Mov10 in Xenopus 
embryos leads to a severe gastrulation defect and failure of the embryo to undergo 
neurulation, possibly due to the misregulation of the maternal to zygotic transition (MZT) 
where one proposed mechanism involves the degradation of maternal mRNAs by RISC 
to allow zygotic transcription to begin [7]; [8]. Loss of zygotic Mov10 in Xenopus leads to 
defects in the differentiation of the retina and abnormalities in brain development. These 
data agree with our findings in mice where in addition to being essential for early 
development, Mov10 expression was found to be significantly elevated in the brain 
shortly after birth through adolescence [6]. We propose that Mov10 plays a vital role in 
gastrulation and normal CNS development. 
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3.3 Results 
Mov10 is required for normal gastrulation and neural tube formation 
Based on our finding that Mov10 knockouts show early embryonic lethality in mice, we 
decided to use Xenopus laevis to study the cause of this lethality because of its 
accessible, external mode of development. We introduced either a control- or a Mov10 
translation blocking morpholino into one-cell Xenopus embryos, which targeted 
maternal as well as zygotic mRNA transcripts of Mov10 to prevent them from being 
translated. In contrast to the control embryos (Fig. 3.1A-F), the translation blocking 
morpholino (m-MO) disrupted the completion of gastrulation, leading to extrusion of 
central yolk cells (Fig.3.1G-L). Time-lapse imaging of the m-MO treated embryos 
showed that gastrulation is initiated but invagination appeared to proceed in a more 
uniform, symmetrical fashion around the blastopore, as indicated by a complete ring of 
dark pigmentation, when compared to the asymmetrical appearance found in control 
embryos (Supplemental videos 3.1 and 3.2, Fig.3.1A-L).  Additionally, there is no 
distinct formation of Brachet’s cleft at the blastopore lip (compare Fig. 3.1K to 3.1E) 
indicating that vegetal rotation is delayed and limited in extent. As the blastopore closes, 
which is driven primarily by convergent thickening, it subsequently reopens in the m-MO 
treated embryos to generate a central mass of exposed endodermal cells (compare 
Fig.3.1, M-P, Supplemental videos 3.1 and 3.2)  
During normal development, cells of the notochord undergo convergent 
extension (CE) and the notochord shears posteriorly along the anterior-posterior axis 
with respect to the adjacent paraxial mesoderm. This does not appear to occur in the m-
MO treated embryos, where late involution of the axial and paraxial mesoderm is 
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prevented [9] (see Fig. 3.1B-H, Q-R). In normal embryos, tissue separation occurs to 
permit involution of marginal zone tissues, and the notochord acts as a zipper to pull 
together the paraxial somitic files at the midline. The location of these cells can be 
visualized by immunofluorescence using the Tor70 and 12-101 antibodies, which stain 
the notochord and somites respectively (Fig.3.1Q) [9, 10]. In contrast, in the m-MO 
treated embryos mesodermal tissues fail to undergo the initial CE, and the notochord 
and somitic mesoderm remain separated and subsequently undergo later CE to reopen 
the blastopore, where these tissues come to lie at the lateral sides of the open 
blastopore (Fig.3.1R). As a result, the defective embryos exhibited a “ring” or “boat-
shaped” phenotype (Fig.3.1N, P). Together, these findings indicate that Mov10 is 
required early during development for normal gastrulation and neural tube formation.  
We were able to rescue these defects by co-injecting Mov10 mRNA designed to be 
resistant to m-MO action (Fig.3.2). We saw a dose dependent increase in the rescued 
phenotype, as we injected a greater amount of Mov10 mRNA (Fig.3.2A) suggesting that 
the gastrulation defect is a direct result of the absence of Mov10. 
 The timing of Mov10’s role in Xenopus development (Stage 10) coincides with 
the Maternal to Zygotic Transition (MZT)—the process where maternal mRNAs are 
degraded—to allow continued development now driven by zygotic transcripts [11]. 
Elimination of maternal transcripts occurs at the start of MZT and continues until after 
Early Gastrula Transition (EGT) [7, 8]. Early zygotic transcription is coupled with the 
rapid miRNA-mediated degradation of maternal targets, as exemplified in Xenopus by 
miR-427-mediated degradation of cyclin A1 [12]. Since Mov10 and Ago2 cooperate to 
regulate transcripts through the miRNA pathway [13], we examined whether Mov10 may 
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be involved in MZT using the Hydroxyurea (HU) assay. HU induces apoptosis in 
embryos after the maternally-encoded apoptotic inhibitors are degraded at MZT [14] 
(Fig.3.3A). Thus, if a protein involved in the degradation of maternal mRNAs is absent, 
the embryo is protected from HU-induced apoptosis at Stage 9.5 (EGT), as shown 
previously for B56-epsilon mRNA [15] (Fig.3.3B-D). In the case of Mov10, m-MO 
injected into one cell of a 2-cell embryo showed a normal pigmented appearance in the 
viable progeny of the injected cell (green arrow), suggesting that the maternal apoptotic 
inhibitors were not degraded, thus, MZT was blocked. In contrast, the uninjected side 
(white arrow) underwent HU-induced apoptosis (Fig.3.3E-G). The apoptotic-resistance 
of the m-MO and B56-epsilon injected embryos showed that MZT is delayed and 
implicates Mov10 in MZT.  We verified this by examining the effect of m-MO on cyclin 
A1 mRNA, a target that contains a single miR-427 binding site that is normally degraded 
at the onset of zygotic transcription [12]. In m-MO treated embryos, cyclin A1 mRNA 
levels remained high at Stages 8-11 compared to controls, where the levels decreased 
drastically as zygotic transcription begins (Fig.3.3H). We conclude that Mov10 appears 
to be required for MZT, possibly by mediating RISC activity.  
To examine the global effect of Mov10 loss on mRNAs at this stage, we isolated 
total RNA from Stage 10.5 control and m-MO treated embryos for RNA-seq. As 
expected for a miRNA-mediated regulatory event, Mov10 knockout embryos showed a 
significant upregulation of mRNAs compared to controls both at a 1.5-fold and a 10-fold 
cut-off (Fig.3.3I). Gene ontology analysis of the upregulated genes included RNAs 
involved in cellular movements, extracellular matrix, actin-filament based processes and 
cell adhesion under the category of “Biological processes” (Fig.3.4). Under the category 
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“Molecular function,” RNAs for calcium binding and actin filament binding are also 
significantly increased. Since activation of the egg at the onset of fertilization causes an 
increase in intracellular calcium levels, perturbation of these RNAs should be expected 
to affect signaling cascades necessary for multiple events including cytoskeletal 
rearrangements [8]. The misregulated genes could thus contribute to the defects seen 
in gastrulation. These data suggest that Mov10 affects MZT through the RISC pathway, 
which subsequently cause pleiotropic effects leading to defective gastrulation and 
neurulation during embryonic development.  
 
Zygotic Mov10 is required for normal CNS development 
We next examined the effect of zygotic Mov10 knockdown using a splice-
blocking morpholino that targets the 5’ splice junction between the third and fourth exon 
resulting in a downstream frameshift and degradation of the zygotic pre-mRNA 
(hereafter, z-MO) (Fig 3.5E). Xenopus embryos were injected with control morpholino or 
z-MO at the one-cell stage, which allows them to progress past MZT, and then 
examined at the tadpole stage, where the effect of a zygotic knockdown might be seen 
(stage 36; Fig.3.5A-D). Mov10 targeting by this morpholino was confirmed by RT-PCR 
(Fig.3.5E). The z-MO treated embryos hatch normally and show muscle contractility. 
Interestingly however, Mov10 z-MO treated embryos showed a significantly smaller eye 
diameter compared to control-morpholino injected embryos (Fig.3.5 A,B,F). This may be 
relevant to Mov10’s role in the CNS since retinal tissue is derived from the 
diencephalon, which is a component of the forebrain. In a recent study we showed that 
Mov10 plays a role in the development of the CNS [6]. Our data agree with that study 
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where whole-mount in-situ hybridization of Mov10 in Xenopus tail-bud stage shows 
expression in the eye anlage and nervous system [16]. In addition to these defects, we 
also observed that the z-MO treated embryos had a significantly smaller anterior-
posterior body length compared to controls (Fig.3.5G). 
 To further characterize the eye size, as well as query for internal brain defects, 
we sectioned and stained control-morpholino and Mov10 z-MO-treated embryos. 
Normal differentiation and layering of the retina was not typically observed in the z-MO 
treated embryos (compare Fig.3.6A to 3.6D). Though the overall brain morphology was 
not affected, we observed a thickening of the ventricular zone (vz) (compare Fig.3.6B to 
3.6E). The ventricular zone is a transient embryonic tissue layer immediately 
surrounding the ventricle that contains neural stem cells [17, 18]. As the neural stem 
cells become depleted through their differentiation into neurons, the ventricular zone 
becomes diminished [19]. To examine the identity of the cells in the Xenopus ventricular 
zone, we examined the cells for expression of Sox3 {SRY (sex determining region Y)-
box 3}, a marker for neural precursor cells [20-22], and for Myt1 (myelin transcription 
factor 1), a marker for primary differentiated neurons [21, 23]. In control MO-injected 
Xenopus, we observed Sox3 staining in ventricular cells while Myt1-staining excluded 
the ventricular zone and was seen in the marginal zone (Fig 3.7A-C, J-L). In contrast in 
the z-MO treated embryos, there is more extensive staining with Sox3 in ventricular 
cells including in the more ventral regions (Fig 3.7D-I) when compared to controls (Fig 
3.7A-C). The staining with Myt1 appears similar between the control and z-MO treated 
embryos (compare Fig 3.7J-L with Fig 3.7M-O). The difference in Sox3 expression 
could suggest abnormal patterns of proliferation of the neural precursors when Mov10 is 
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absent. These findings support our conclusion that Mov10 is required for normal CNS 
development as observed in mice [6] . We also saw reduced parachordal cartilages 
surrounding the notochord in the z-MO treated embryos (Fig.3.6C to 3.6F) [24, 25]. 
Parachordal cartilages expand and form the basal plate of the chondrocranium and are 
important for craniofacial development [26].  
 
3.4 Discussion 
The embryonic lethality observed in Xenopus is consistent with the 
developmental increase in Mov10 mRNA levels seen in both X. laevis and X. tropicalis, 
suggesting an important role for Mov10 during development [27]. Elimination of 
maternal Mov10 leads to gastrulation defects and a failure of the embryo to undergo 
normal CE, which leads to a failure in neurulation (Fig.3.1). Like other RISC 
components--Dicer, Drosha and Ago2--loss of Mov10 causes embryonic lethality in 
mouse [6] [28-30]. The regulation of MZT by Mov10 suggests a role similar to that of 
Ago2 at the two-cell stage in mouse embryos [31]. Additionally, our data shows that the 
absence of Mov10 at the onset of development results in an overall increase in mRNA 
levels around MZT consistent with RISC function (Fig. 3.3I). This increase in mRNA 
levels could be due to misregulation of multiple maternal transcripts or a few key 
regulatory transcripts that then leads to large-scale defects at gastrulation. Mov10 has 
low expression levels in the adult mouse brain [6] similar to what is reported in the Allen 
brain atlas [32, 33]; however, there is an approximately 40-fold increase in Mov10 levels 
in P0-P3 mouse brain [6], suggesting an important role in brain development. 
Furthermore, the knockdown of zygotic Mov10 in Xenopus leads to eye defects, as well 
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as abnormal organization of the ventricular zone in the brain, which we confirmed with a 
neuronal precursor marker (Fig. 3.6 and 3.7). These data suggest a conserved role for 
Mov10 in the normal development of the brain. 
In summary, we show a key role for Mov10 in gastrulation and in the central 
nervous system during embryonic development in Xenopus, which supports our earlier 
study in mouse [6]. Knockdown of maternal Mov10 in Xenopus embryos leads to 
gastrulation defects and a failure to neurulate possibly due to pleiotropic effects. The 
large-scale disorganization of cytoskeletal mRNAs could be due to Mov10’s role in 
miRNA-mediated regulation of MZT. In addition, zygotic Mov10 is necessary for normal 
head and eye development in Xenopus consistent with its function in the mouse [6].  
 
3.5 Experimental Procedures 
Microinjection of X. laevis embryos 
Morpholinos were dissolved in RNase-free H20 to a stock concentration of 2mM to 
facilitate co-injection with RNA at various concentrations. Depending on the experiment, 
either zygotes or embryos at the two-cell stage (stage 2, all stages follow [34] were 
immersed in 5% Ficoll solution (diluted with 1/20X Normal Amphibian Medium; Slack, 
1984) and immobilized in rounded pits made in clay-lined petri dishes [35, 36]. Graded 
concentrations of morpholinos or RNAs were injected using glass microinjection 
needles (World Precision Instruments, Inc, Sarasota, FL; #TW100F-4) with a Narishige 
micromanipulator (Narishige USA, East Meadow, NY) and Harvard Apparatus into 
either fertilized eggs or unilaterally into single cells at the two-cell stage for the 
hydroxyurea assay (described below in Hydroxyurea Assay).  Following injections, 
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embryos were transferred to 1/20X NAM solution to recover and cultured at room 
temperature or 16°C with daily 1/20X NAM changes until various time points were 
reached for analysis.  The experiments were carried out with embryos from at least 6 
biological replicates, i.e., six mating pairings. 
Morpholino Oligonucleotide Design 
The Mov10 RISC complex RNA helicase sequence is publicly available from Xenbase 
in the Xenopus laevis J-strain version 9.1 genome data [37].  Following analysis, this 
sequence data was used to design a translation blocking morpholino (m-MO, Gene 
Tools, LLC) that targets bases -17 to 9 of the Xenopus laevis Mov10 transcript.  Splice 
blocking morpholinos (z-MO) were also designed to target the intron/exon 4 region.  The 
design also includes an incorporated 5’- fluorescein tag (green) to allow imaging of cells 
expressing the morpholino.  Additionally, a standard fluorescein-tagged random control 
morpholino (Con) was used as a negative control (targeting the human globin intron).  
This control morpholino is not known to target any X. laevis sequences and has been 
used in previous experiments to assay for potential non-specific effects from the 
injections or possible toxicity [38].   
Generation of X. laevis Mov10 mRNA 
An altered full-length synthetic RNA of X. laevis Mov10 was generated for injection into 
X. laevis embryos. The sequence immediately downstream of the Mov10 start site was 
altered by changing the third/wobble amino acid while preserving the original protein 
coding sequence to prevent Mov10 translation blocking Morpholino hybridization (IDT 
gBlocks). The full-length altered cDNA was synthesized in two pieces (fragment 1 = 
 91 
1221nt; fragment 2 = 1987nt) and Gibson assembly (New England Biolabs, Ipswich, 
MA) was used to directionally ligate the gBlocks into the pCS2+ vector between the ClaI 
and XhoI restriction sites.  Sequences were verified by the Roy J. Carver Biotechnology 
Center (University of Illinois, Urbana, IL).  Rescue RNA was made from PCR-amplified 
template (SP6 and T3 primers).  The SP6 mMessage mMachine kit (Thermo/Ambion) 
was used to transcribe RNA, followed by purification of the RNA with the RNease 
MinElute Cleanup Kit (Qiagen). 
Xenopus histology  
Stage 36 tadpoles were fixed in 4% Paraformaldehyde in 1X PBS for 1 hour at RT, 
followed by three washes in 1X PBS for 15 min each. The tadpoles were serially 
dehydrated in 30%, 50% and 70% ethanol for an hour each at RT and stored in 70% 
ethanol. Body length and eye diameter were measured using ImageJ software. For 
whole mount histology, the tadpoles were incubated in 95% ethanol for 15min followed 
by three 100% ethanol washes for 15min each. The tadpoles were then moved to 
xylene and incubated for 30min with fresh changes of xylene every 10 min. This was 
followed by a 6 hour incubation in 50% Paraplast plus xylene solution at 60deg. The 
tadpoles were then moved to fresh Paraplast plus twice for 6 hours each at 60 degrees 
before embedding in plastic boats. Sections were prepared using a Spencer 820 rotary 
microtome, affixed to slides and dried overnight. The sections were deparaffinized and 
stained with Hematoxylin & Eosin staining. The staining was performed using 
Hematoxylin 7211 and Eosin Y reagents (ThermoSceintific, Waltham, MA) according to 
the manufacturers protocol. The images were captured using a Spot digital camera 
(Diagnostic Instruments, Inc., Sterling Heights, MI). A biological replicate of 25 – 30 
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Stage 36 tadpoles from three different matings were scored. 
Xenopus embryo IHC 
Embryos were devitellinized and fixed in 4% paraformaldehyde in PBS for 15 min at RT, 
followed by three washes of 1X PBS for 15min each. The embryos were sequentially 
dehydrated using 25%, 50%, 75%, 95% and 100% ethanol for 15 min each. The 
embryos were prepared for paraffin embedding and sectioned as described in the 
Xenopus histology methods. For, IHC, the sections were deparaffinized using xylene 
and rehydrated before Heat-induced Antigen retrieval in 1X citrate buffer (pH-6.0) [39]. 
The slides were stained using the following primary antibodies at 0.5ug/ml- Tor-70 (a 
kind gift from Prof. Ray Keller), 12-101 (Developmental Studies Hybridoma Bank, Iowa), 
at 1:500 dilution for Sox3 and Myt1 (kind gift from Prof. Klymkowsky and Prof. 
Papalapoulo respectively) [40]. The secondary antibodies were Alexa Flour 488 
(Jackson Immunoresearch, West Grove, PA) and RITC-conjugated IgM specific 
antibody (Jackson Immuoresearch) used at a concentration of 1:200. The experiment 
was done using 6 biological replicates, i.e., six mating pairs for each condition. 
Hydroxyurea Assay 
Two-cell Xenopus embryos were rinsed in 1X MMR and injected using glass 
microinjection needles with a Narishige micromanipulator and Harvard Apparatus 
microinjector. The embryos were transferred to 0.25X MMR containing a final 
concentration of 30mM hydroxyurea (Sigma Aldrich, St. Louis, MO) and incubated at 16 
degrees. The embryos were monitored closely till they reached Stage 9.5 and imaged. 
The experiment was conducted thrice using three biological replicates. 
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RNA- Sequencing and Analysis of Xenopus total RNA 
Total RNA was isolated from three biological replicates of Stage 10.5 embryos from WT 
and m-MO injected embryos using the TRIZOL (Ambion, Thermo Fisher Scientific, 
Waltham, MO) reagent. The samples were sequenced at the High-Throughput 
Sequencing and Genotyping Unit of the Carver Biotechnology Center at the University 
of Illinois. Strand-specific single-end libraries were prepared using the TruSeq Stranded 
mRNAseq Sample Prep kit (Illumina, San Diego, CA). The libraries were quantitated by 
qPCR, pooled in equimolar amounts and sequenced on 2 lanes of a HiSeq 4000 
(Illumina; sequencing kit version 1), generating over 780 million 100 bp single-end 
reads. Fastq files were generated and demultiplexed per sample with the bcl2fastq 
v2.17.1.14 Conversion Software (Illumina), which also trims Illumina adapters from the 
reads and removes any resulting sequences shorter than 35 bp. All bases across the 
reads showed quality scores greater than Q30 (FASTQC version 0.11.4) so quality 
trimming was not performed. The Xenopus laevis reference genome version 9.1 was 
downloaded from Xenbase [37] along with the version 1.8.3 gene models containing 
45,099 genes (as of August 9th, 2016, this appears to be renamed to version 1.8.3.1). 
The gene models were converted from gff3 to gtf format using the gff_read program 
from cufflinks (version 2.2.1) [41]. Reads were aligned to the genome using STAR 
(version 2.5.2a) [42] using parameters --sjdbGTFfeatureExon CDS, --
sjdbGTFtagExonParentGene gene_id and –quantMode GeneCounts, the last of which 
outputs read counts per gene_id, summing over all coding sequences (CDS) of the 
gene.The read counts were input into R 3.3.1 [43] for data pre-processing and statistical 
analysis using packages from Bioconductor [44], as indicated below. Initial quality 
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control analysis indicated that one of the three Mov10 morpholino (m-MO) treated 
replicates had many fewer reads and looked very different and therefore it was removed 
from the analysis. Genes without 1 Count Per Million (CPM) mapped reads in at least 
two of the 5 samples were filtered out; 19,368 of the 45,099 genes passed this filter and 
were analyzed using edgeR 3.16.0.[45] using the quasi-likelihood pipeline [46, 47] that 
also accounted for the total library size for each sample and an extra TMM 
normalization factor [45] for any biases due to changes in total RNA composition of the 
samples. Due to the large number of genes with very small fold-changes, we tested for 
differential expression of at least 1.5 fold and at least 10 fold change up or down, using 
the TREAT method [48] adapted for quasi-likelihood F-tests [46]. Adjustment for 
multiple testing was done using the False Discovery Rate method [49].  
Additional annotation information for the X. laevis genes was pulled from 2 
sources that were published concurrently: blast mappings to human genes done by [50] 
and gene symbols assigned by Xenbase in gene model annotation 1.8.3, which was a 
major update to the annotated gene symbols by merging 2 databases and human 
curation by three experts [51]. Supplemental Table S1 deposited by Ding et al. (2016) in 
NCBI’s Gene Expression Omnibus (GSE75278) contains X. laevis IDs from “genome 
assembly JGI9.1”, human protein IDs, human gene symbols and descriptions. These X. 
laevis IDs are actually the Xenopus Gene Nomenclature Committee’s symbols, but for 
the Xenbase version 1.8.0 gene models (Name attribute in 
Xlaevisv1.8.Named.gene.gff3.gz). The major annotation update to Xenbase version 
1.8.3 only changed the symbols, not the number or locations of genes, so the internal ID 
attribute is the same for all 1.8 gene model sets and was used to link the human gene 
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symbols to our differential expression results. Xenbase recently published a small 
version upgrade (1.8.3.2) to the gene model set we had used (1.8.3.1), which corrected 
gene symbols for five gene models.  We used the gene symbols from 1.8.3.2, which are 
based on human gene nomenclature [37]. Both sets of gene symbols, Ding et al. (2016) 
and Xenbase, needed minor correcting to remove leading/trailing white spaces, X. 
laevis’ sub-genome extensions and to fix capitalization differences with the symbols in 
Bioconductor’s org.Hs.eg.db_3.4.0 annotation package. Both sets of gene symbols also 
contained older symbols that org.Hs.eg.db_3.4.0 listed as retired aliases; we updated 
the older symbols to current symbols if possible, also resolving a few aliases that 
mapped to more than one current symbol by inspecting the gene description from Ding 
et al. (2016). Comparisons of the Ding et al. (2016) and Xenbase annotations showed 
overwhelming agreement between the two with 73.8% of genes annotated to the same 
symbol or no symbol (Supplemental Table 3.1). Only 2.6% of genes were annotated to 
different symbols by the two sources, and many of these were just different members of 
the same gene family (e.g., DOCK6 vs DOCK7). In these cases we preferentially used 
the Ding et al. (2016) annotation because it annotated more genes overall and had 
descriptions listed as well. The 23.6% of genes annotated with a symbol in only once 
source were assigned that symbol. The selected gene symbols were then used to pull 
NCBI Entrez Gene IDs, gene names and Gene Ontology terms from 
org.Hs.eg.db_3.4.0.  
 Of the 19,368 X. laevis gene models that were expressed in our samples, only 
1,470 were not annotated to a human symbol and the rest were annotated to only 
10,935 unique human genes due to the tetraploid genome of X. laevis. To do over-
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representation testing on GO term pathways based on human annotations, each unique 
human symbol was deemed “significant” if at least of the X. laevis genes mapping to it 
had FDR p < 0.05 for the > 1.5 FC test. 4,596 human genes were called significant 
under these criteria, irrespective of direction of change. When directionality is taken into 
account, 140 human genes had significant X. laevis genes changing in both directions; 
this is not terribly surprising given the nature of mapping to human genes and both 
results could be true if the gene has multiple splice variants. We did not try to resolve 
these discrepancies but instead counted the genes as both significantly up (2,826 
genes) and down (1,883) when conducting GO testing separately based on direction. 
Over-representation testing was done separately for the all-significant, up- significant 
and down- significant gene sets using the 10,935 unique genes as the background. The 
GOstat package’s (v 2.40.0) conditional hypergeometric testing was performed to 
reduce the redundancy of related GO terms. Comparison of GO terms’ raw p-values 
between the all, up and down gene sets was done to see which GO terms were specific 
to the direction of change and which included genes changing in both directions. 
Heatmaps of –log10 (p-values) across the 3 gene sets were made separately for BP, 
MF and CC categories; GO terms with raw p-values < 0.001 in any gene set were 
included for MF and CC, but due to the larger number of BP terms, only those with raw 
p-values < 0.0001 in any gene set were included in the heatmap.  
All of the R codes necessary for the above analyses are in Supplemental File 3.3 
(Skariah_GSE86382_Bioc3.4.txt).  No additional files are needed because the codes 
show how to download the necessary sample counts and annotations from GEO and 
Xenbase. The codes produce the results presented in Skariah et al. when run with R 
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3.3.1 / Bioconductor 3.4. There are currently reviewer links Reviewer / collaborator link 
to Xenopus RNAseq GSE86382 
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3.6 Figures  
 
Figure 3.1.  Maternal Mov10 is required for gastrulation and neural tube formation. 
A-F) Whole-mount images of control embryos undergoing normal gastrulation. G-L) 
Whole-mount images of maternal Mov10 knockdown (m-MO) embryos that have failed 
to complete gastrulation. M-P) Dorsal, whole-mount images from Control (Con) (M) and 
m-MO treated embryo (N), Stage 10.5, Lateral view of a Con embryo (O), View from 
anterior end of m-MO treated embryo showing boat-shaped phenotype (P). d-dorsal, v-
ventral, a-anterior, p-posterior, yc- yolk cells, cg-cement gland. The dotted lines show 
the plane of section in Q and R. Q) Section through a control (Con) showing notochord 
and somites joined along the AP axis, stage 10.5. Antibody to Tor70 recognizes 
notochord {in red}; Antibody 12-101 recognizes somatic mesoderm {in green}; DAPI in 
blue R) Section through a typical m-MO embryo showing failure to undergo normal 
convergent extension and form a nervous system.   
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Figure 3.1 (cont.) - Bl-blastopore lip, bp-blastopore, cg-cement gland, nt-neural tube, a-
anterior, p-posterior. Sm-somite, nc-notochord, nt-neural tube. Scale bar in R = 120um 
(A-L), 450um (M-N), 440um (O-P), 80um (Q-R). 
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Figure 3.2. Co-injection of Mov10 mRNA rescues the gastrulation defect. A) 
Rescue of m-MO by introduction of 125pg and 375pg of Mov10 mRNA. Error bars 
represent SEM, p value < 0.001 (Student’s t-test, two-tailed). B-D) Whole-mount images 
of Stage12 Con (B), m-Mo (C) and rescue embryos co-injected with Mov10 mRNA 
(250pg) (D). np- neural plate, bp-blastopore, yp- yolk plug. Scale bar in D = 120um. 
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Figure 3.3. Mov10 regulates MZT through RISC. A) Schematic of the Hydroxyurea 
assay. EGT- Early Gastrula Transition, HU-Hydroxyurea. 
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Figure 3.3 (cont.)- B-D) Whole mount images of two-cell embryos, where only one cell 
was injected with morpholino targeting a positive regulator of MZT (B56ε). A total of 22 
embryos were injected and 21 of those showed the expected phenotype. E-G) Images 
of two-cell embryos, where only one cell was injected with m-MO. Scale bar- 300um. A 
total of 22 embryos were injected and all of them showed the expected phenotype. 
Green arrow- MO-injected side, white arrowhead- uninjected side. H) qRT-PCR of cyclin 
A1 levels in control and m-MO embryos at indicated stages. Error bars represent SEM. 
NS- Not significant, p *<0.05 (Student’s t-test, two-tailed).  I) Differential expression 
results for Mov10 morpholino treated (Mov10) vs. control (C), X-axis-average 
expression value (TMM-normalized Counts Per Million, log2 scale) of each X. laevis 
gene and y-axis is log2 (Mov10/C). Each point is a single gene: groups of genes colored 
red or blue had significantly greater than or less than 1.5 FC difference (unlogged), 
respectively. Groups of genes colored pink or light blue also had significantly greater 
than or less than 10 FC difference (unlogged), respectively. The numbers of genes 
listed at the +/- 1.5 FC level include the genes with +/- 10 FC. 
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Figure 3.4. Mov10 regulates mRNAs involved in cytoskeletal function in Xenopus. 
A) Heat maps of –log10 (p-values) showing the comparison of all, up and down gene 
sets from X.laevis for Biological Process (BP) category. Due to the larger number of BP 
terms, only those with raw p-values < 0.0001 in any gene set were included in the 
heatmap. B) Heat maps of –log10 (p-values) showing the comparison of all, up and 
down gene sets from X.laevis for Molecular Function (MF) category. GO terms with raw 
p-values < 0.001 in any gene set were included for MF. The arrows point to relevant GO 
categories. Arrows indicate GO terms of interest. (see text) See Table S1 
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Figure 3.5. Knockdown of zygotic Mov10 causes decrease in eye and body size. 
A) Whole-mount images of control morpholino (Con) injected tadpoles at Stage 36. A 
total of 46 tadpoles were analyzed.  
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Figure 3.5. (cont.) - B) Whole-mount images of zygotic Mov10 knockdown (z-MO) 
tadpoles at Stage 36. A total of 48 tadpoles were analyzed and 45 of them showed a 
small eye phenotype. (C, D) Fluorescein images of the tadpoles from A and B. E) RT-
PCR from control or z-MO treated embryos using Mov10 primers. ODC (Ornithine 
Decarboxylase) was used as a control. F) Graph showing eye diameter in um from Con 
injected and zygotic Mov10 knockout (z-MO) embryos. Error bars represent SEM, p 
**<0.05 (Student’s t-test, two-tailed). G) Graph showing overall anterior-posterior (AP) 
length in mm from Control and zygotic morpholino treated embryos measured at Stage 
36.  A total of 67 tadpoles were analyzed. Error bars represent SEM, p **<0.05 
(Student’s t-test, two-tailed). Scale bar in D = 800um 
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Figure 3.6. Knockout of zygotic Mov10 leads to defects in the eye and brain 
structure. A) H&E stain of Con MO injected embryos showing sections of eye (A), brain 
(B) and notochord (C). (D-F) H&E stain of z-MO injected embryos showing sections of 
eye (D), brain (E) and notochord (F). Many of the z-MO injected embryos did not exhibit 
well-defined layers in the retina. gc-ganglion cell layer, ip-inner plexiform layer, bc-
bipolar cell layer, op-outer plexiform layer, pr-photoreceptor, rp- retinal pigment 
epithelium, mz-marginal zone, vz-ventricular zone, pc-parachordal cartilage, nc-
notochord, “dl”-disorganized layering in D. Scale bar in F = 100um (A-B and D-E), and 
170um (C-F).  
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Fig 3.7. Knockout of Mov10 shows abnormal staining of neuronal precursors in 
the ventricular zone. A-C) Control section shows the junction of the forebrain and 
midbrain and a few Sox3 positive precursors associated with the beginning of the 
midbrain at the bottom of the figure. A) Sox3 positive neuronal precursor cells 
surrounding the ventricle. B) DAPI staining of the same region. C) Merge of Sox3 and 
DAPI stains. D-I) Sections from a similar region as shown in (A) from two representative 
z-MO treated tadpoles stained with Sox3 antibody. D,G) Sox3 positive neuronal 
precursors, E, H) DAPI staining, F, I) Merge of Sox3 and DAPI. Notice the enhanced 
staining of Sox3 in the more ventral regions compared to the control embryo. J) A stage 
36 tadpole showing the plane of sectioning for A through P.  K-M) Myt1 staining for 
differentiated neurons in a control midbrain region. K) Myt1 positive differentiated 
neurons, L) DAPI staining, M) Merge. N-P) Sections from midbrain in z-MO treated 
tadpoles. N) Myt1 positive differentiated neurons. O) DAPI staining. P) Merge. vn- 
ventricle, vz-ventricular zone, rp-roof plate, fp- floor plate. Scale bar in P = 40um. 
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CHAPTER 4 
UNDERSTANDING THE ROLE OF FMRP IN THE miRNA PATHWAY 
 
4.1 Abstract 
The Fragile X Mental Retardation Protein (FMRP) is critical for normal cognition and its 
absence leads to Fragile X Syndrome (FXS), the most common form of inherited 
intellectual disability. FMRP is an RNA binding protein that binds ~4% of brain mRNAs 
and regulates their translation. We have previously shown that FMRP controls the 
translation of neuronal mRNAs through the microRNA (miRNA) pathway and this 
regulation is based on its association with Mov10 and Ago2. This study attempts to 
answer some key questions about the nature of FMRP’s interaction with the RNA 
components of the miRNA pathway. Here, we show that immunoprecipitated FMRP and 
the phosphorylated forms of FMRP associate with a neuronal precursor miRNA 125b 
(pre-miRNA125b) in a northwestern assay. However, neither the full length FMRP nor 
the K-Homology RNA binding domains of FMRP can directly bind to either pre-
miRNA125b or miR125b in a filter binding assay. We also see differential binding of pre-
miRNA125b to heterogeneous nuclear Ribonucleoprotein A1 (hnRNPA1) depending on 
whether hnRNPA1 bound to the phosphorylated or unphosphorylated form of FMRP. 
These findings show conclusively that FMRP does not directly bind precursor or 
miRNAs. Additionally, along with evidence from published studies and our observation 
of differential precursor binding to hnRNPA1, we propose a possible model for FMRP 
and hnRNPA1 in neurons. 
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4.2 Introduction 
Fragile X Mental Retardation Syndrome (FXS) accounts for almost 20% of all X-linked 
mental retardation pathologies. The most significant clinical features of FXS are 
developmental delays and intellectual disability [1]. FXS is caused by the transcriptional 
silencing of the FMR1 gene, which encodes an RNA-binding protein called the Fragile X 
Mental Retardation Protein (FMRP). FMRP binds to ~4% of neuronal mRNAs and 
regulates their activity-dependent local translation at synapses. Consequently, the 
absence of FMRP affects local protein synthesis leading to spine abnormalities and 
aberrant synaptic plasticity as seen in the Fmr1 knockout mouse model [2-4]. FMRP 
contains two tandem RNA binding KH (K-homology) domains, KH1 and KH2, and a C-
terminal RGG box domain. In vitro RNA selection and mapping experiments have 
shown that the RGG domain binds G-quadruplex containing mRNAs while the second 
KH domain (KH2) binds an RNA structure called a loop-loop pseudoknot or “kissing 
complex” (Fig.4.3) [5, 6]. The KH2 domain alone is sufficient to bind kissing complex 
RNAs and suggests that the KH1 domain is not involved in this interaction. Thus there is 
no identified RNA target for the KH1 domain of FMRP yet [6].  
The miRNA pathway regulates ~60% of expressed genes employing small, non-
coding RNAs that are largely repressors of translation [7]. miRNAs are genomically 
encoded, small (~20-24 nt) RNAs that base pair to sequences in the 3’ UTR of mRNAs 
to regulate their translation [8]. miRNAs are synthesized as primary microRNAs (pri-
miRNA) that are then processed into 70-80 nt precursor miRNAs (pre-miRs), exported 
to the cytoplasm and further processed into miRNAs by specific protein complexes 
acting at each step [9]. The first studies to show a connection between FMRP and the 
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miRNA pathway opened up the possibility of diseases arising from defective miRNA 
mediated regulation [10-12]. More recent studies have also shown evidence that FMRP 
associates with precursor miRNAs and miRNAs and that the phosphorylation of FMRP 
mediates this association [13-15]. Perhaps the most relevant supporting study that 
motivated this work was the finding of pre-miRs and miRs cross-linked to FMRP in 
iCLIP studies [16], suggesting that Fmrp might directly bind these important RISC factor 
components. However, none of these studies have specifically addressed if FMRP is a 
key player that binds directly to miRNAs or pre-miRs to affect translation or if it is an 
auxiliary protein that associates with the components of the miRNA pathway and uses 
this as a flexible platform to guide itself to its targets. This question is even more 
relevant since it is becoming increasingly evident that RNA binding proteins like FMRP 
have intrinsically disordered protein regions that coordinate RNA binding besides their 
canonical RNA binding domains [17]. Additionally, it has been known that FMRP is 
present in cellular substructures like messenger Ribonucleoprotein (mRNP) complexes 
and neuronal RNA granules [18, 19]. These structures are proposed to form from the 
interactions between the disordered regions of proteins, alternately called prion-like or 
Low Complexity (LC) domains that undergo reversible phase-transitions [20-22]. FMRP 
contains LC domains in the C-terminal half of the protein and can assemble into 
complexes with other LC domain containing proteins like FUS [20]. Thus it is 
conceivable that FMRP might be indirectly associating with miRNA components in the 
RNA-induced Silencing Complex (RISC).  
In this study we show conclusively that FMRP’s role in the miRNA pathway does 
not involve direct binding to either pre-miRNAs or miRNAs. Additionally, the WT FMRP 
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complex also contains hnRNPA1 based on Liquid Chromatography-Mass Spectrometry 
(LC-MS) analysis (our data) and hnRNPA1 binds to pre-miRNA as well in our 
northwestern assay. Based on the size of hnRNPA1 protein that is bound to pre-miR, it 
appears that it might be phosphorylated. More interestingly, there is a differential 
binding of pre-miRNA between hnRNPA1 and the phosphorylated and 
unphosphorylated forms of FMRP. These data show that the role of FMRP is to assist in 
miRNA-mediated regulation and also suggests that FMRP and hnRNPA1 might interact 
through their LC domains and have a phosphorylation- dependent role in this pathway. 
 
4.3 Results  
Immunoprecipitated FMRP and its phosphomimics bind pre-miR125b. 
It has been widely reported that miRNAs and pre-miRs are found associated with FMRP 
in cell culture studies as well as in brain [14, 16]. Additionally, miR125b was enriched in 
FMRP immunoprecipitates and was found to target the 3’UTR of the NR2A subunit of 
NMDA receptors thereby regulating its translational levels. However, the interaction 
might be an indirect one since FMRP also associates with many components of the 
miRNA pathway including an RNA-dependent interaction with the miRNA effector 
protein AGO2 [23]. Additionally, the phosphorylation status of FMRP was shown to 
regulate the miRNA-mediated suppression of PSD-95 mRNA at synapses [15]. In order 
to query this association, we over expressed FLAG-tagged WT FMRP along with its 
phosphomimics (referred to as ALA and ASP hereon) in HEK293T cells and 
immunoprecipitated using an antibody to FMRP. The ALA and ASP- substituted FMRP 
represent the constitutively unphosphorylated (ALA) and phosphorylated (ASP) forms of 
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FMRP since they carry a single Serine to Alanine (S499A) or a Serine to Aspartate 
(S499D) mutation at the highly conserved phosphorylation site in the C-terminus of 
FMRP [24]. The immunoprecipitated proteins were resolved by SDS-PAGE, transferred 
to PVDF membrane and probed with 32P-labeled pre-miR125b, a brain-specific 
precursor miRNA [14]. This is referred to as a Northwestern assay because a labeled 
RNA is used to probe immobilized proteins to determine if they can directly bind the 
RNA [25]. All the three forms of FMRP bound pre-miR125b probe (Fig.4.1, top panel). 
The binding between the three proteins was not significantly different as determined by 
the Western blot (Fig.4.1, bottom panel) and densitometry. We also tested 32P-labelled 
miR125b in the northwestern assay but did not find any signal, possibly due to the 
degradation of the 22nt miRNA probe. As controls to confirm the specificity of the 
northwestern signal, we performed the same assay using SC1 RNA, a known interactor 
of both FMRP and its paralog FXR1 along with BSA and the KH domains of FMRP, 
which do not bind SC1 [26]. We find that SC1 RNA bound to recombinant FXR1P with 
increasing concentrations of protein but as expected it did not bind either BSA or the KH 
domains of FMRP (Fig.4.2). Thus the signal seen in the northwestern assay shows 
specificity for genuine RNA protein interactions only. This data supports the possibility 
that FMRP could directly bind pre-miRs or miRNAs as seen in other studies [14, 16].  
 
The KH1/KH2 domains of FMRP do not bind either miR125b or pre-miR125b. 
Of the three RNA binding domains of FMRP, the KH1 domain does not have an 
identified RNA substrate while the KH2 domain binds an in vitro- selected RNA ligand 
termed “kissing complex” RNA [6]. Pre-miRs have a stem-loop structure that resembles 
 116 
part of the kissing complex loop-loop pseudoknot structure (Fig.4.3). Also, FMRP was 
found to recognize the loop region of the kissing complex since disruption of the loop 
abrogated the binding of FMRP. We wanted to test if the naturally occurring pre-miR 
structure could be a substrate for the KH domains of FMRP.  In order to check for direct 
binding, human FMRP KH1/ KH2 domains were expressed as His-tagged fusion 
proteins and purified as described in the methods section for use in the filter-binding 
assay. The purified protein was passed through a second heparin column and 
quantified using BSA standards on a Commassie gel (Fig.4.4). The RNA substrates 
were generated by in vitro transcription reaction and end labeled with 32P- gamma-ATP. 
Both the recombinant FMRP KH1/KH2 and the radiolabeled RNA substrates were used 
in a nitrocellulose filter-binding assay to test for direct binding. Our results clearly show 
that miR125b and pre-miR125b2 do not bind the KH1/KH2 domains of FMRP as 
compared to kissing complex RNA (kc2) and a mutated form (kc2m) where the loop-
loop interaction is disrupted. The result also shows that pre-miRs are not a preferred 
substrate of either the KH1 or KH2 domains of FMRP. 
 
Full length FMRP does not bind pre-miR125b or miR-125b directly. 
Having established that the pre-miRs or miRNA is not a substrate for the KH domains, 
we tested the full length FMRP in filter binding assays to see if other domains might 
participate in direct binding to precursor or miR125b. We used G-quadruplex containing 
SC1 and SC1 mutant (SC1m) as controls in this assay. SC1 RNA binds to the RGG box 
of FMRP with very high affinity [5, 27, 28]. As shown in Fig.4.5, we did not see binding 
of the full-length recombinant FMRP to either substrates while the control RNAs 
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behaved as expected. These results show that none of the other domains of FMRP can 
interact with either precursor miRNA or miRNA substrates and suggest that FMRP is 
indirectly associated with miRNAs via complexed proteins. 
 
WT FMRP and its phosphomimcs show differential hnRNPA1 binding. 
To further investigate the association of FMRP within the complex, we analyzed the 
second protein that also bound pre-miR125b in the Northwestern assay at 
approximately 38kDa in all the three immunoprecipitates (Fig.4.6, top panel). This 
protein was identified as hnRNPA1 by LC-MS and confirmed by Western blot using an 
antibody specific for hnRNPA1 (Fig.4.6, bottom panel). This suggests that FMRP is in a 
complex with hnRNPA1 both of which are recognized and bound by labeled pre-miR. 
The association of FMRP and hnRNPA1 has been shown before and is RNA-mediated 
[29]. Here we see that the constitutively phosphorylated and unphosphorylated forms of 
FMRP also associate with hnRNPA1. hnRNPA1 associated with unphosphorylated  
FMRP (ALA) shows an approximately 4-fold increase in signal for pre-miR125b binding 
than the WT and ASP FMRP based on densitometry (Fig.4.6, top panel). The signals 
between WT and ASP are not significantly different and the western blot of FMRP and 
hnRNPA1 shows that the loading is equal for all lanes (Fig.4.6, bottom panel). 
Additionally, the precursor bound hnRNPA1 band migrated slightly slower than the 
expected size of 34kDa for hnRNPA1 (compare bottom panel western with the 
northwestern) and is the right size for hnRNPA1 phosphorylated by Casein Kinase II 
(CKII) in vitro [30]. We hypothesize that unphosphorylated FMRP preferentially 
associates with phosphorylated hnRNPA1, which has bound more readily by pre-miR. 
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Phosphorylation of hnRNPA1 is required for its nuclear export [31-33]. In addition, 
nuclear hnRNPA1 is involved in the processing of primary miRNA 18a (pri-miR18a) and 
in vivo crosslinking and immunoprecipitation showed that it bound to the precursor of 
this miRNA as well [34]. Primary miRNA processing happens in the nucleus and it is 
likely that the phosphorylated hnRNPA1 bound to the precursor is exported out of the 
nucleus and forms a complex with the unphosphorylated FMRP via interactions 
between the LC domains. Both FMRP and hnRNPA1 contain LC domains in their C-
terminal regions and are capable of forming hydrogels using the biotinylated-isoxazole 
(b-isox) chemical [20, 21]. These chemically induced hydrogels emulate the cellular 
aggregates called RNA granules, which are classified based on their composition. The 
neuronal granules contain FMRP and mRNAs along with other translational initiation 
factors and ribosomal subunits and are transported to the synapse for activity-mediated 
translation [35]. More recently, it was shown that pre-miRs are present at the base of 
spines at synapses and are rapidly processed on stimulation [36]. Interestingly, this 
study used pre-miR18a, which is bound by hnRNPA1 [34]. Based on these observations 
and our findings we propose a model wherein FMRP and phosphorylated hnRNPA1 
accumulate in neuronal granules with a specific precursor and are transported along the 
dendrite to synaptic spines. Dicer that is present at the synapse might rapidly process 
the pre-miR to miRNA releasing it to AGO2 for miRNA Recognition Element (MRE) 
binding.  Additionally, FMRP might become phosphorylated at the same time to cause 
the dissociation of both Dicer and hnRNPA1 [13] (Fig.6). The complex is now held in a 
translationally repressed condition awaiting an activation signal that will cause 
dissociation of FMRP and AGO2 and activate translation of the mRNA (Fig.4.7) [15]. 
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4.4 Discussion 
Fragile X syndrome is caused by the absence of FMRP, which is a selective RNA 
binding protein. The loss of FMRP leads to aberrant translation of its mRNA targets, 
which further leads to the functional deficits that characterize this syndrome [37, 38]. 
One of the key regulators of translation in the cell is the miRNA and the effector proteins 
associated with this pathway. Despite the growing evidence of an association of FMRP 
with the miRNA pathway, there is no definite mechanism of how this key regulator of 
translation might be operating within this pathway. In order to dissect out the role of 
FMRP in the miRNA pathway, we carried out Northwestern assays to establish whether 
immunoprecipitated FMRP binds to the brain specific pre-miR 125b. Since the 
phosphorylation status of FMRP has been implicated in miRNA-mediated regulation, we 
also tested the constitutively phosphorylated and unphosphorylated mimics of FMRP in 
this assay. We find that all three forms of FMRP bound pre-miR125b (Fig.4.1). This data 
confirms earlier findings and suggests that FMRP may be associating with miRNA or 
pre-miRs. However, the interaction might be indirect since FMRP associates with 
various components of the RISC pathway [10, 11, 14]. We addressed this question by 
carrying out a direct binding assay using the minimal KH1/KH2 RNA binding domains of 
FMRP and in vitro transcribed brain-specific miRNA to begin with. In the same assay, 
we also tested for pre-miRNA as a possible cellular substrate for the uncharacterized 
KH1 domain of FMRP. Our results show conclusively that the tandem KH domains of 
FMRP do not bind either miRNAs or pre-miRNA and suggests that FMRP does not bind 
miRNAs or pre-miRNAs via its KH domains (Fig.4.4). However, it is possible that the 
binding may be occurring through other parts of the protein and so we performed the 
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same assay using full length FMRP synthesized in Sf9 cells.  Again, we find that both 
pre-miR125b and miR125b do not associate with full-length FMRP (Fig.4.5), showing 
that FMRP is not a direct interactor of the RNA components of the RISC pathway. Thus 
our data suggests that since FMRP is an mRNA binding protein and present in neuronal 
or transport RNA granules, its role in the complex is that of an auxillary protein that is 
bound to the mRNA cargoes within the complex. The question of how it becomes a part 
of this complex is perhaps answered by the observation that the only other protein that 
bound pre-miR125b and was seen at detectable levels in the FMRP immunoprecipitate 
was hnRNPA1 (Fig.4.6). There is evidence of such an association in astrocytic GW-182 
containing Bodies (GWB), which are reported as both nuclear and cytoplasmic 
structures that also contain components of the RISC pathway [39, 40].  Such structures 
are hypothesized to form from phase transitions occurring between LC domain 
containing proteins within cells [20, 21]. It is conceivable that FMRP-containing bodies 
found in neurons may exhibit heterogeneity in their components and may interact with 
GW bodies as well. Based on this finding, we propose a possible model for the 
interaction of FMRP and phosphorylated hnRNPA1 in precursor transport and 
processing in neurons (Fig.4.7). 
 
 
 
 
 
 
 121 
4.5 Methods 
Purification of recombinant KH1/KH2 domains of FMRP 
The pET21b encoding the KH1/KH2 domains of FMRP (a gift from Dr. Jen Darnell) was 
transformed in BL21DE3 and cultured at 37°C, 250 rpm in Luria-Bertani media (LB, 
Fischer Scientific) containing 200ug/mL ampicillin  (Amp, Fisher Scientific). The clone 
was frozen at -80°C as 100uL aliquots. For purification, the 100uL aliquot was added to 
a 5ml LB (Amp) broth and grown overnight at 37°C, 250 rpm. The next day 2.5ml of the 
overnight culture was inoculated into 250mL LB (Amp) and grown for 3hrs at 37°C to an 
O.D600 of 0.6. The culture was then induced with 1mM IPTG and grown at R.T for 2hrs. 
The induced cells were then pelleted at 5000rpm for 10min and stored at 4°C on ice and 
processed the next day. The pellet was resuspended in 2X lysis buffer (20mM HEPES, 
600mM LiCl, 10mM imidazole, 10% glycerol, pH-7.5) along with 1mg/ml benzamidine, 
1mM PMSF, 5ug/ml DNAse I and one complete™ mini protease inhibitor cocktail tablet 
(Roche Diagnostics). The cells were sonicated (Cole-Parmer Ultrasonic processor) 
thrice for 30 seconds each in 10 sec pulses with 10 sec on ice. The crude lysate was 
spun at 11000rpm for 60min at 4°C and the supernatant was mixed in a tube with 5ml of 
Ni-NTA resin (Invitrogen) that had been pre-equilibrated with Binding buffer (10mM 
HEPES, 300mM LiCl, 5% glycerol, 20mM Imidazole, 1mg/mL Benzamidine, pH – 8.0). 
The protein was bound to the resin by gently rotating the tube at 4°C for an hour. The 
resin was then packed in a column and allowed to settle as the lysate was collected in a 
tube. The resin was washed with 10 column volumes of buffer 1 (10mM HEPES, 
300mM LiCl, 5% glycerol, 10mM Imidazole, 1mg/mL Benzamidine, pH – 8.0) at a flow 
rate of 0.5ml/min. This was followed by 10 column volumes of Buffer II (10mM HEPES, 
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300mM LiCl, 5% glycerol, 20mM Imidazole, 1mg/mL Benzamidine, pH – 8.0) and 10 
column volumes of Buffer III (10mM HEPES, 300mM LiCl, 5% glycerol, 25mM 
Imidazole, 1mg/mL Benzamidine, pH – 8.0) at a rate of 0.5ml/min.  A final wash was 
done with 5 column volumes of Buffer IV (10mM HEPES, 300mM LiCl, 5% glycerol, 
50mM Imidazole, 1mg/mL Benzamidine, pH – 8.0) at 1ml/min. The protein was then 
eluted at the same rate with the Elution buffer (10mM HEPES, 300mM LiCl, 5% 
glycerol, 100mM Imidazole, 1mg/mL Benzamidine, pH – 8.0) in 3ml fractions. The 
elutions were analyzed on a 12% SDS gel and the fractions containing the purified 
KH1/KH2 domain (24kDa) were pooled and cleaned over a heparin column (GE 
healthcare) and exchanged into 1X SBB buffer (200mM potassium acetate, 5mM 
Magnesium acetate and 50mM Tris acetate, pH 7.4). The fractions were then quantified 
by using BSA standards on a Commassie gel with the Image J software. 
 
Purification of recombinant full-length FMRP  
Sf9 cells from log phase (1.5-2.5x106 cells/ml) with >95% viability was used for 
transfection in unsupplemented Grace Insect cell media (Invitrogen). Briefly, 8x105 cells 
were plated in 6-well plates and allowed to attach to the dishes for 15min. Plating media 
containing 1.5ml of 10% FCS supplemented Grace and 8.5ml of unsupplemented Grace 
was prepared and added to the cells after they attached completely. Cellfectin reagent 
(Invitrogen) was used to transfect 1-2ug of purified FMRP-Bacmid DNA. The cells were 
incubated at 27 degrees for 4 hours and the media was replaced with supplemented 
Grace media. The cells were incubated for 72hrs and observed for signs of viral 
infection. After 72hrs, the cells were transferred to a 15ml conical and spun down. The 
 123 
supernatant was filtered through a 0.2u filter to collect the P1 (passage1) viral 
concentrate. The P1 stock was then amplified by infecting Sf9 cells at Multiplicity of 
Infection (MOI) of 0.1 for 72hrs in spinner flasks. The P2 supernatant is collected and 
assayed using a Viral Plaque assay to determine the viral titer. Based on the assay, the 
virus can be amplified once more to reach a titer of 107-108 pfu/ml for protein 
purification. FMRP purification was done from 500ml Sf9 cells using an MOI of 1 in 
spinner flasks and buffers described in [16]. The purification was done using Cobalt-
TALON (Clontech) columns and FMRP was eluted in 300mM imidazole and dialyzed 
with glycerol containing buffer before freezing in aliquots. The fractions were quantified 
by using BSA standards on a Commassie gel with the Image J software. 
 
In vitro transcription of 32 P- labeled RNA ligands 
Transcription templates for pre- miRs125b1 and b2 were generated by PCR using the 
pED368 FhSynRedW mir-125b1 and pED249 FhSynRedW mir-125b2 constructs 
respectively (gift from Edbauer). The primers used for pre-miR125b2 are:  
TAATACGACTCACTATAGGGCCTAGTCCCTGAGACCCTAAC 
GCCTAGGTCCCAAGAGCCTG. The primers TAATACGACTCACTATAGGG and 
TCACAAGTTAGGGTCTCAGGGACCCTATAGTGAGTCGTATTA were annealed to 
generate the mir125b template. The DNA templates were purified over G-25 (GE 
healthcare) columns. In vitro transcription reactions were done using 1ug of DNA 
template in a 25uL reaction with 1mM dNTPs (Roche), 1uL of T7 RNA polymerase 
(Roche) and 1uL of RNAsin (Promega). The reactions were incubated at 37°C for 2hrs 
and treated with 1uL of RQ1 DNAse (Promega) for 10min at the same temperature. The 
 124 
RNA templates were dephosphorylated using Shrimp Alkaline Phosphatase (USB) at 
37°C for 90min and deactivated at 65°C for 15min. The dephosphorylated RNA 
templates were end labeled using 32P-gamma-ATP and 1uL of T4 PNK (NEB) and 
cleaned on a G-25 column (GE healthcare) before Phenol chloroform and ethanol 
precipitation. The RNA was precipitated overnight with 100% ethanol and 10% Sodium 
acetate (0.5M) at -80°C. The pellet was washed with 70% ethanol, dried and 
resuspended in DEPC treated water. 
 
Northwestern Assay 
Immunoprecipitated proteins were separated on a 4-20% gradient gel and transferred to 
a PVDF membrane overnight at 45mV /4°C. The membrane was then blocked with 5% 
fat-free milk containing 20ug/ml yeast tRNA (Sigma-Aldrich) for 1hr at room temperature 
(RT). The membrane was subsequently washed with EB buffer (10mM HEPES- pH-7.6, 
3mM MgCl2, 40mM KCL, 1mM DTT, 0.2% Nonidet P-40/ IGEPAL, 1mM PMSF) for 1 
hour at RT.  32P labeled probe for the sense strand of pre-miR125b was added at 
2ng/ml (5x106 counts per million/cpm) along with 20ug/ml yeast tRNA in EB buffer to the 
membrane and incubated for 3hrs at RT. The buffer was removed and the membrane 
was washed extensively with 3-4 buffer changes for 15min each at RT till the counts 
read roughly 1000 cpm or less on a Geiger counter. The membrane was briefly air-dried 
and exposed to an autoradiograph for 18hrs before imaging.  
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Filter Binding Assay 
The Filter-binding Assay was carried out as per the protocol described in [26]. Briefly, 
10ul of 10,000cpm (1-5 fmol) of heat-renatured, 32P-labeled in-vitro transcribed RNA 
was added to serial dilutions of either full length FMRP or KH1/KH2 –FMRP and 
incubated at room temperature for 10min. Samples were filtered through MF 
nitrocellulose HAWP-02500 membranes (Merck-Millipore, Billerica, MA, USA) on 
Millipore vacuum manifold and washed thrice before quantifying by scintillation 
counting. Total RNA counts were estimated by spotting 10ul of RNA on a filter disc. A 
background control (without protein) was also used in the filtration assay. Data are 
expressed as percentage of the Total RNA and plotted using Excel (Microsoft).  
 
Immunoprecipitation of WT FMRP and phosphomimics 
HEK293T cells were plated at a density of 5x106 cells and transfected after 24hrs with 
plasmids bearing WT-FMRP, ALA and ASP phosphomimics using lipofectamine in Opti-
MEM (Gibco). The cells were recovered with Trypsin after 24hrs growth in complete 
DMEM media and lysed in lysis buffer (50mM Tris-pH 7.6, 150mM NaCl, 30mM EDTA, 
0.5% Triton X 100). The cells were spun down to remove nuclei and the supernatant 
was transferred to tubes containing 50ul of 50% Protein A Sepharose beads coupled to 
7G 1-1 antibody to FMRP. The lysate was immunoprecipitated for 2 hours at 4°C. After 
2 hrs, the tubes were spun and the lysated removed. The beads were washed thrice 
with lysis buffer for 5 min each and boiled in Laemmli buffer. 
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4.6 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Northwestern of FMRP and FMRP phosphomimic (Asp) and mutant 
(Ala) shows binding to pre-miR125b2 –  (Top) Northwestern assay with pre-miR125b. 
The first two lanes are controls with the beads used for immunoprecipitation alone 
(Beads) and an irrelevant antibody coupled to the beads (Mock). The remaining three 
lanes show FLAG-tagged WT, ALA and ASP FMRP, which was pulled down with a 
FMRP-specific antibody and probed with 32P-labeled pre-miR125b. The bottom panel is 
a Western blot using an antibody specific to FMRP. 
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Figure 4.2. Control experiment showing the specificity of Northwestern assay- 
The top panel is a northwestern assay with SC1 RNA. The first three lanes contain 
recombinant FXR1 (rFXR1) protein at 1ug (1), 2ug(2) and 3ug(3) concentrations. The 
next three lanes contain 1ug, 2ug and 3ug of BSA as a control and the last three lanes 
contain recombinant KH1/KH2 domains of FMRP at 1ug, 2ug and 3ug concentrations. 
The blot was probed with 32P-labeled SC1 RNA. The bottom panels show a Commassie 
gel loaded in the same manner as the northwestern gel. 
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Figure 4.3.  Structure of the Kissing complex RNA and pre-miRNA 124- Structure of 
the Kissing complex RNA [156] and a pre-miR with the microRNA sequence boxed 
(from TargetScan). 
 
 
 
 
 
 
 
	
 129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. The KH1/KH2 domain of FMRP does not bind precursor or mature 
miRNAs- Graph depicting the results of a filter-binding assay using kc2, kc2m and 
precursor and mature 125b RNA with increasing amounts of recombinant KH1/KH2 
domain of FMRP (n=3). Error bras represent SD (Student’s t-test, two-tailed). 
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Figure 4.5. Full length FMRP does not bind precursor or mature miRNA- A) 
Coommassie gel showing varying concentrations of recombinant full-length FMRP and 
BSA as a standard for protein estimation. B) Graph showing representative data from a 
filter- binding assay using SC1, SC1mut and precursor and mature miR125b RNA with 
increasing concentrations of FMRP. This experiment was done twice with two separate 
protein preparations. 
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Figure 4.6. Northwestern assay showing the co-bound FMRP and hnRNPA1 with 
pre-miR125b – Top panel shows the northwestern assay using 32P labeled 
premiR125b. The first lane is a control with beads used for conjugating the antibody 
(Beads), the second lane is an immunoprecipitation using an irrelevant antibody (Mock) 
and the next three lanes are immunoprecipitation using an FMRP-specific antibody to 
WT, ALA and ASP-FMRP. The bottom panels show the western blots using FMRP and 
hnRNPA1 antibody. 
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Figure 4.7. Proposed model for the FMRP-hnRNPA1 complex in precursor 
transport and processing – 1) Phosphorylated hnRNPA1 binds to precursor in the 
nucleus and is transported out into the cytoplasm [31]. 2) FMRP with its bound mRNA 
cargo and transport proteins associates with phosphorylated hnRNPA1 and precursor 
miRNA. 3) The complex is transported down the dendrite to the base of synaptic spines. 
4) Dicer present at the spines associates with the precursor-containing complex and 
processes the precursor to miRNA in an activity dependent manner [186]. 5 and 6) At 
the same time, FMRP becomes phosphorylated and dissociates from both Dicer [13] 
and hnRNPA1 and moves to a repressed complex containing AGO2 bound to the 
mRNA-miRNA complex. 7) Dephosphorylated hnRNPA1 is transported back to the 
nucleus and phosphorylated to repeat the cycle. 
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CHAPTER 5 
CONCLUSION 
This thesis is the first systematic study of the RNA helicase Mov10 both in the 
developing embryo and in the postnatal brain. The introductory chapter outlines the 
pertinent studies that have been done to understand the function of Mov10 and 
concludes that this is a multifunctional RNA helicase that has multiple important 
functions in the cell. It also points to the gaps in the field regarding the role of Mov10 in 
brain, especially it’s crucial function in suppressing retroelements which are active in 
differentiating neurons as well as it’s function in regulating neuronal mRNA transcripts 
through the miRNA pathway. In Chapter 2 of this work, I have attempted to address 
these gaps by studying Mov10 in the developing postnatal brain and show that nuclear 
Mov10 is indeed critical for suppressing retroelements. More interestingly, cytoplasmic 
Mov10 binds and regulates cytoskeletal mRNAs in the developing brain providing the 
first report of a role for Mov10 in cytoskeletal dynamics in the developing brain. These 
findings along with the behavioral defects seen in the Mov10 heterozygote mice lends 
precedence to a possible role for Mov10 in diseases of the brain that have underlying 
cytoarchitectural deficits. Additional hints to what the exact molecular nature of this 
function might be comes from the established role that Mov10 has in the miRNA 
pathway. In support of this, preliminary data is provided in Chapter 2 and Appendix A 
that strongly suggests that Mov10, FMRP and Ago2 could function together to regulate 
translation of cytoskeletal mRNAs in brain. Future work in this direction would require a 
systematic target-based approach to identify key transcripts that might contribute to 
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formation of normal neuronal cytoskeleton such as Map1b using cell and neuronal 
cultures.  Additionally, conditional knockout of Mov10 in brain followed by structural 
mapping and behavioral studies would be required to confirm the function of Mov10 in 
the development of normal brain circuitry. 
An evolutionarily conserved role for Mov10 in the developing embryo was 
discovered in the studies described primarily in Chapter 3 and partly in Chapter 2 of this 
thesis, where the absence of Mov10 in both mouse and Xenopus led to early embryonic 
lethality. This is yet another novel role for Mov10 at a completely different stage in 
organismal development. However, there is a common theme of cytoskeletal defects 
observed at this stage just as in the developing brain. These defects may arise as a 
result of the mysregulation of miRNA-mediated degradation of transcripts at the 
Maternal to Zygotic Transition (MZT) leading to indirect effects later in gastrulation or 
could also be a result of the direct mysregulation of key cytoskeletal transcripts by 
Mov10 at gastrulation. In order to delineate these possibilities a systematic study of the 
effect of Mov10 knockdown at specific stages in embryonic development would be 
necessary. Thus, the generation of a conditional Mov10 knockout mouse will be crucial 
to study the exact molecular roles that Mov10 plays both at the embryonic and postnatal 
stages of development.  
Chapter 4 of this thesis attempts to address an outstanding question in the field 
about the nature of the interaction of FMRP and the RNA components of the RISC 
pathway.  This is answered by using recombinant proteins and in vitro transcribed 
precursor and miRNA molecules in a filter-binding assay. The data shown here proves 
conclusively that FMRP does not bind either precursor miRNA or miRNA directly but 
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acts within the complex as an accessory protein. Additional data points to a possible 
role for FMRP and its phosphomimcs that are bound to hnRNPA1 in assisting with the 
transport and processing of precursor miRNAs. Mov10 is also a part of the RISC 
complex and associates with FMRP and is found at synapses. It would be interesting to 
dissect out the composition of these different complexes that work together and 
determine how their dynamics change in a spatial and temporal manner. Future work 
would also require confirming the different steps of the proposed model using primary 
neuronal cultures from Fmr1 knockout mice and activity-mediated stimulation to show 
the role of FMRP in precursor processing. 
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APPENDIX A 
 
 
N-TERM OF MOV10 RESCUES NEURITE DEFECT 
	
 
Mov10 is required for neurite outgrowth in N2a cells (Fig.2.4) and FMRP and Mov10 
may participate in the miRNA pathway to regulate mRNA targets involved in neurite 
outgrowth (Fig.2.5). In support of this finding, we have data showing that the N-terminus 
of Mov10 associates with FMRP and that the N-terminus of FMRP associates with 
Ago2. Both these interactions are RNA-dependent (Kenny PJ, unpublished data). 
Additionally, the N-terminal half of Mov10 has a proposed role in perhaps being a 
platform for interaction with other proteins as shown in viruses [1]. We hypothesized that 
the N-terminal half of Mov10 might be interacting with FMRP bound to Ago2 to regulate 
the common cytoskeletal targets that we find in our bioinformatics analysis (Fig.2.5B). 
To test this we transfected Mov10 knockout N2a cells with the N-terminal half and the 
C-terminal half of Mov10 along with the helicase mutant, where a mutation of the 
conserved Lysine to Alanine in Motif I (K531A in mouse) abrogates the helicase activity 
[2]. We find that the N-terminal half of Mov10 alone can rescue the neurite length 
phenotype to WT levels (Fig A.1- compare Mov10 KO to Mov10 KO+ N-term). The 
helicase-dead mutant also shows recovery of neurite length to WT levels suggesting 
that the helicase activity is not required for this function (Fig.A.1- compare Mov10 KO 
and Mov10 KO+K531A) rather the presence of the N-terminal half in this construct is 
responsible for the rescue. This is further supported by the observation that the helicase 
domain containing C-terminus of Mov10 also does not rescue the neurite length 
(Fig.A.1- compare Mov10 KO to Mov10 KO+ C-term). This data shows that the 
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interaction of the N-terminus of Mov10 with FMRP that is bound to Ago2 might be 
modulating the translation of the common cytoskeletal mRNAs. This is being tested by 
ongoing investigations at the mRNA and protein levels for these targets in the lab. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1.  The N-terminus of Mov10 is required for regulating neurite outgrowth. 
The top panel is a graph showing the mean neurite length in um for the various 
conditions described on the X-axis. The bottom panel shows the Western blot of Mov10 
under the different conditions. The HA-tagged C-term and N-term Mov10 blots were 
probed using an antibody to HA. eIf5α was used as a loading control. A total of 800 or 
more differentiated neurons were counted from six experiments and at least 20 images 
were counted per condition. Statistics used was one-way ANOVA. 
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A.1 Methods 
Counting of neurite length for N2a 
Neuro2a wild type and Mov10 knockout cells were plated in a 24 well plate at a density 
of 1.5x104 cells per well and incubated for 24 hours at 37 degrees in DMEM (with 10% 
FCS). One set of the Mov10 knockout wells were transfected with the K531A, HA-C-
term Mov10 and HA-N-term Mov10 plasmids using Lipofectamine (2000) before 
differentiating with DMEM (2% FCS) and 20uM Retinoic Acid (Sigma-Aldrich) a day 
later. The cells were allowed to differentiate for 48 hours and imaged under transmitted 
light using an EVOS cell-imaging microscope. The images were anonymized and 
analyzed by an experimenter blinded to the conditions using the Axiovision Image 
analysis software. A total of 800 or more differentiated neurons were counted from six 
experiments and at least 20 images were counted per condition. 
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